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Abstract 
Uremic toxin retention and an altered gut microbiota are suspected to influence cytochrome 
P450s (CYPs) contributing to the unpredictable pharmacokinetics in chronic kidney disease 
(CKD). We aim to characterize dysbiosis and uremia to elucidate associations between CYP 
expression and CKD progression. Rats fed control or CKD-inducing diet were subsequently 
sacrificed across five time points over 42 days. CYP expression and activity were compared to 
alterations in the 1) plasma and liver metabolome and 2) bacterial microbiota. CYP3A2 and 
CYP2C11, respectively, were downregulated in CKD by ≥76% (p<0.001) simultaneously or 
slightly premature to CKD onset defined by creatinine. Metabolite profiles were altered before 
the gut microbiota and gut-derived uremic toxins including indoxyl sulfate, phenyl sulfate and 
4-ethylphenyl sulfate correlated with CYP3A2 or CYP2C11. Identified bacterial genera, 
Turicibacter and Parabacteroides, characterized CKD and require future study. In conclusion, 
CYP3A2 and CYP2C11 are downregulated prior to dysbiosis but correlate with select uremic 
toxins. 
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Chapter 1  
1 Introduction 
1.1 Preface 
Understanding biological systems is quickly becoming a multidimensional and 
multidisciplinary effort. With the wealth of technological advances in biological 
methodology, study of whole-organism physiology has become a reality. The combination 
of “omics” methods such as metabolomics and sequencing of the microbiome has provided 
the opportunity to compare whole-system host physiological processes. Our era of public 
databases and data sharing allows blinded discovery of complex biological fingerprints 
without requiring the identity of any individual sequence or metabolite. This exploratory 
and hypothesis-forming science supports big questions about phenotype and disease states 
with relation to dependent bodily systems such as the gut microbiome and host metabolome 
(Nicholson et al., 2005). In this thesis, detectable host gut bacteria and metabolomic 
profiles are characterized and related to altered drug metabolism over the progression of 
chronic kidney disease (CKD). 
1.2 Renal Physiology 
The kidney is an essential organ responsible for excretion of harmful biological waste 
products while simultaneously maintaining water, electrolyte, nutrient and pH balance 
(Reese et al., 2011). Nephrons, the functional units of the kidney, filter water, urea and all 
other molecules excluding large proteins and red blood cells at the glomerulus. 
Immediately following filtration, reabsorption back into the bloodstream begins in the 
proximal tubule where active transport of sodium stimulates the reabsorption of water, 
chloride, glucose and amino acids (Reese et al., 2011). Most water reabsorption occurs in 
the descending limb of the loop of Henle, effectively concentrating the urine. Further 
reabsorption of sodium and chloride ions occurs in the water impermeable ascending limb. 
The distal tubule performs fine adjustments in salt and ion concentrations by activation of 
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the renin-angiotensin-aldosterone system (RAAS) (Reese et al., 2011). In short, macula 
densa cells detect decreased sodium levels of the filtrate in the distal tubule and signal to 
juxtaglomerular cells of the afferent or efferent arteriole to produce renin. Renin released 
into the bloodstream sends a signalling cascade through angiotensinogen, angiotensin I, 
angiotensin II and finally aldosterone to increase the reabsorption of sodium at the distal 
tubule. The filtrate then reaches the collecting duct where it may be further influenced by 
antidiuretic hormone (ADH) or atrial natriuretic peptide (ANP) depending on the persisting 
imbalance of either nutrients or arterial pressure, respectively (Reese et al., 2011). Urea, a 
small molecule responsible for removing harmful ammonia is recycled from the collecting 
duct filtrate and used to increase the osmolarity at the earlier descending loop of Henle 
allowing for more water to be reabsorbed (Reese et al., 2011). After the urea helps reabsorb 
water, it returns to the final filtrate and is excreted in the urine. Besides maintaining water, 
pH and electrolyte balance, the kidney eliminates toxic metabolites, controls blood pressure 
and produces renin, erythropoietin, prostaglandins and activated vitamin D (Reese et al., 
2011). 
1.3 Chronic Kidney Disease 
1.3.1 Prevalence 
Chronic kidney disease (CKD) is a progressive and irreversible loss of kidney function 
heavily associated with age, obesity and diabetes (Levey et al., 2003; O’Hare et al., 2007; 
Zhou et al., 2008; Kopple, 2010; Hahr & Molitch, 2015). An estimated three million 
Canadians (12.5%) are affected by renal insufficiency or complete renal failure but 
inconsistencies in identifying earlier stages of CKD suggest prevalence may be even higher 
(Jha et al., 2013; Arora et al., 2013). In 2015, the number of Canadians aged 65 years or 
older (16.1%) was higher than those aged 0-14 for the first time in history, and projections 
suggest this will increase to 20.1% by 2024 (Statistics Canada, 2015). In addition to an 
aging population, a staggering 24.8% of Canadians over 18 years of age have a body mass 
index classified as obese which increased by 17.5% from 2003 (OECD, 2011). As a result, 
the prevalence of insulin resistance in the form of diabetes mellitus, the most common 
cause of CKD, is also expected to increase (Hahr & Molitch, 2015; Wouters et al., 2016). 
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Thus, the national health care burden of CKD is extensive and projected to increase along 
with these associated demographics (Manns et al., 2007). Alongside Canada, 16% of the 
global population is affected by CKD in other aging or obese countries such as Taiwan, 
USA, Japan, Portugal, Belgium and South Korea (Jha et al., 2013). More recently, 
developing countries such as Nepal, Sri Lanka, Mexico and many locations in India are 
experiencing prevalent CKD because of insufficient health care and access to renal 
therapies (Abraham et al., 2016). 
1.3.2 Causes & Comorbidities 
There is no singular blanketing CKD pathophysiology due to the many causes and 
comorbidities across individuals. Kidney damage is most commonly mediated by 
hypertension or diabetic nephropathy although acute kidney injury (AKI), lupus nephritis 
or genetic variations such as polycystic kidney disease may translate into CKD later in life 
(Levey et al., 2003). 
Hypertension is both a stimulus and consequence of CKD. Persistently increased blood 
pressure can induce thickening and subsequent narrowing of the arterioles entering the 
glomerulus. This decreases the glomerular pressure reducing the amount of filtrate entering 
the proximal tubule and sequentially decreases urine output (Hall et al., 2014). A healthy 
kidney experiencing reduced glomerular pressure produces renin to retain sodium and 
water to increase blood volume and heart rate. The injured kidney will also activate the 
RAAS system but this increases the blood flow through narrow arteries promoting fluid 
retention (Sereno et al., 2016). Thus, an increased fluid volume worsens glomerular 
pressure, further contributing to hypertension and leading to edema, cardiovascular stress 
and heart disease (Tedla et al., 2011). Additionally, lack of blood flow to the kidney can 
cause glomerulosclerosis or hardening of the capillaries required for filtration. This triggers 
ischemia and eventually nephron death (Sugiyama et al., 1996; Tedla et al., 2011).  
Diabetic nephropathy (DN) is an anticipated outcome for 40% of diabetics (Gross et al., 
2005; Hahr & Molitch, 2015). Although controversial, some research suggests that strictly 
maintaining glucose levels reduces the rate at which pathologies such as mesangial cell 
expansion and proliferation, podocyte death and glomerulosclerosis manifest. However, 
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other factors such as hormone regulation and inflammation are also suspected to have a 
role in DN onset (Schena, 2005). DN can be organized into four severity classes, the final 
being glomerulosclerosis which eventually leads to nephron death (Tervaert et al., 2010).  
1.3.3 Detection & Progression 
CKD is an irreversible disease because following nephron death, undamaged nephrons 
acquire the added filtration load in a condition called glomerular hyperfiltration (Kopple, 
2010). This usually occurs in early stages of CKD when the kidney has reduced but 
adequate function. Unfortunately, overworked nephrons eventually succumb to 
glomerulosclerosis, vascular sclerosis and tubulointerstitial fibrosis responsible for the 
transition into late-stage CKD.  
To eliminate variance caused by multiple pathologies, the National Kidney Foundation has 
clinically defined CKD as a progressive loss of renal function by measuring glomerular 
filtration rate (GFR). The GFR is the volume of filtrate produced by glomeruli over time 
and surface area expressed in units of ml/min/1.73m2. Normal GFR ranges between 120-
130 ml/min/1.73m2, but this decreases with age by about 1ml/min/1.73m2 per year (Levey 
et al., 2003). An estimated GFR (eGFR) is arguably the least invasive and most effective 
method of CKD assessment. It relates patient age, sex, race and body mass with a 
measurement of the disease marker creatinine by a common eGFR calculation. Creatinine 
is a normal by-product of non-enzymatic creatine degradation that remains relatively 
constant from day to day (Wyss & Kaddurah-Daouk, 2000). Creatinine remains the 
biomarker of choice because of its unhindered filtration through the glomerulus and 
minimal reabsorption (Lopez-Giacoman, 2015). However, creatinine has limited accuracy 
not only because it is dependent on diet and muscle mass but it is also secreted via the 
proximal tubule. In severe CKD, hypersecretion of creatinine can exaggerate the estimate 
of GFR (Shemesh et al., 1985). Examples of eGFR calculations are the Modification of 
Diet in Renal Disease (MDRD) equation and Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation, the latter of which is newer and has received more 
support for its improved accuracy over the MDRD method (Stevens et al., 2010; Arora et 
al., 2013). 
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Changes in GFR can be preceded by proteinuria which is known to indicate CKD risk 
earlier than GFR, especially in diabetic patients (Gross et al., 2005). Proteinuria is the 
amount of albumin or any other protein normally unable to escape the bloodstream that is 
allowed to enter the urine due to structural epithelial malfunctions at the glomerulus 
(Satchell & Tooke, 2008). Albuminuria is solely the loss of albumin. Microalbuminuria is 
considered moderately increased and macroalbuminuria severely increased levels of 
albumin (Hahr & Molitch, 2015). Albuminuria is commonly expressed as a ratio of 
albumin to creatinine where a level under 30mg/g is normal, 30-200mg/g is indicative of 
early to moderate CKD and a level over 200mg/g is indicative of late-stage CKD (Levey 
et al., 2003). 
Kidney disease has five clinically identified stages defined by the National Kidney 
Foundation (Levey et al., 2003) (Figure 1.1). Stage 1 represents kidney damage detectable 
by albuminuria but expressing a normal GFR >90ml/min/1.73m2. Stage 2 is kidney damage 
with GFR between 60-89ml/min/1.73m2. To be categorized as having moderate CKD, a 
patient must have a GFR <60ml/min/1.73m2 or kidney damage that has persisted for over 
three months. This definition can also be classified as Stage 3 with a GFR between 30-
59ml/min/1.73m2. Severe CKD begins in Stage 4 with a GFR between 15-
29ml/min/1.73m2 and requires extensive pharmaceutical interventions to combat 
comorbidities such as hypertension, diabetes and cardiovascular diseases (CVD). End-
stage renal disease (ESRD) specifically refers to patients requiring renal replacement 
therapies such as dialysis or kidney transplantation to sustain life and generally include 
Stage 5 CKD patients with kidney failure or a GFR <15ml/min/1.73m2. Dialysis modalities 
include hemodialysis or peritoneal dialysis where the blood of a patient is filtered through 
a dialysis membrane simulating the filtering function of a kidney (Luo et al., 2011). 
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Figure 1.1. Prevalence and clinical stages of CKD. A) Canadian and worldwide prevalence 
of all CKD and CKD stages 1-5. B) Description, GFR and albuminuria guidelines with 
respect to CKD stages 1-5. # Prevalence estimate cannot be reported due to low sample 
size and variability (coefficient of variation > 33.3%); ≈ 0.1% world population. Adapted 
from (Levey et al., 2003; Smink et al., 2012; Arora et al., 2013; Hill et al., 2016). 
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1.3.4 Clinical Manifestations & Uremia 
Nephron loss causes a host of nutrient imbalances that can prove fatal if left untreated. 
Metabolic acidosis and hypocalcaemia will cause bone decalcification and osteodystrophy 
if left unchecked (KDIGO Work Group, 2009). Even more dangerous is the imbalance of 
potassium, sodium and water that can lead to hyperkalemia, peripheral edema, 
hypertension and heart disease (KDIGO Work Group, 2009). The leading cause of death 
in CKD is CVD inflicted by hypertension and largely unknown mechanisms that may be 
related to vitamin D deficiency, anemia, uremia, dyslipidemia, low-grade inflammation or 
hormone imbalances (Gansevoort et al., 2013). Currently, there is no cure for CKD and 
therapeutics focus on the treatment of comorbidities with the aim of delaying disease 
progression into ESRD. 
Uremic syndrome however, remains a clinically challenging symptom to alleviate and 
drives the progression of CKD into ESRD (Meyer & Hostetter, 2007). Uremic syndrome 
manifests when harmful molecules called uremic toxins are permitted to circulate in the 
plasma at abnormally high concentrations regardless of dialysis interventions (Lisowska-
Myjak, 2014). Uremia is the pathological environment of the blood plasma in CKD patients 
experiencing retention of urea and other organic compounds due to a loss of renal clearance 
(Meyer & Hostetter, 2007). The state of uremia has been associated with the activation of 
the immune response and gut microbial alterations (Vitetta & Gobe, 2013), cardiovascular 
events (Ito & Yoshida, 2014), bone toxicity (Barreto et al., 2009a), neurological disorders 
(Bugnicourt et al., 2013) and a host of other manifestations affecting every organ of the 
body (Vanholder & De Smet, 1999; Lisowska-Myjak, 2014). As of 2012, concentrations 
of 88 uremic toxins were identified as abnormal in CKD patients and can be sorted into 
three classes dependent on molecular size and protein binding (Duranton et al., 2012). Free 
water-soluble metabolites such as creatinine and urea have the lowest molecular mass 
(<0.5kDa) and are largely removable by dialysis. Middle molecules range from 0.5-60kDa 
and include small proteins, hormones and cytokines. Protein-bound uremic toxins are often 
of low molecular weight but are bound to larger protein carriers in circulation. Dialysis 
membranes will not allow the removal of albumin; thus, uremic toxins bound to albumin 
are especially difficult to remove from the plasma. Out of the over 88 recognized uremic 
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toxins, 25% are protein-bound and have proven clinically challenging to eliminate with 
traditional dialysis strategies (Duranton et al., 2012). 
1.3.5 Animal Models of CKD 
Models of CKD in rats include 5/6th nephrectomy, diabetic nephropathy and adenine-
induced CKD. The most common 5/6th nephrectomy method surgically removes the top 
and bottom thirds of one kidney and the entire contralateral kidney effectively simulating 
the loss in kidney function although potentially inducing post-surgery stress (Ali et al., 
2013). Diabetic nephropathy models of diabetes-induced kidney disease usually use the 
administration of streptozotocin to cause pancreatic β cell death. Additionally, the diabetic 
nephropathy model although most exemplary of human CKD caused by diabetes, requires 
a timely experimental period to successfully cause CKD that may not occur simultaneously 
across all animals. The newer adenine-induced model of CKD is a less invasive orally 
administered model suggested to provide a more consistent rate of CKD onset than the 
5/6th nephrectomy (Terai et al., 2008). The adenine model of CKD also shows the best 
promise as a progressive CKD model suitable for temporal evaluation due to its timely 
onset in comparison with the diabetic model. Additionally, the adenine model has been 
used to study alterations in DMEs of the liver in the past, providing a clear example of 
severe CKD after 42 days of oral administration (Feere et al., 2015; Velenosi et al., 2016). 
Mechanistically, adenine and its metabolite 2,8-dihydroxyadenine precipitate when 
concentrated at the kidney. This mechanically damages the kidney tubules comparable to 
that inflicted by kidney stones and is thus a tubular model of kidney damage (Engle et al., 
1996; Morishita et al., 2011; Succar et al., 2017).  
1.4 Hepatic Physiology 
Where the kidney is made up of functional units, the liver is made up of cells lining hepatic 
sinusoids organized around hepatic veins. Parenchymal hepatocytes make up the majority 
of the liver volume alongside non-parenchymal sinusoidal endothelial, stellate and Kupffer 
cells which together are responsible for the multitude of hepatic functions (Porth, 2011).  
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Select roles of the liver are important with respect to CKD and kidney physiology. Firstly, 
the liver is responsible for the continuation of the RAAS signalling pathway by production 
of angiotensinogen, the hormone stimulated in response to the release of renin by the 
kidney (Reese et al., 2011). Secondly, the liver’s ability to produce carrier proteins 
synthesized with the purpose of transporting signalling molecules is relevant in CKD. 
Albumin, a highly versatile carrier protein responsible for much of the endogenous and 
xenobiotic transport within the plasma, is the most abundant plasma protein produced by 
the liver (Berg et al., 2012). Since it cannot pass through the glomerulus, albumin can retain 
bound molecules in the plasma, preventing their excretion via the kidney and is particularly 
exaggerated in CKD (Meyer & Hostetter, 2007). The liver is also known for its major roles 
in metabolism. The liver not only handles lipid, carbohydrate and amino acid synthesis and 
degradation but also xenobiotic metabolism (Porth, 2011). An endogenous example is the 
catabolic degradation of amino acids by aminotransferases which release ammonia that is 
excreted as urea through the kidney (Berg et al., 2012). Next, exogenous metabolism by 
specific enzymes produced in the liver will be explicitly discussed. 
1.5 Drug Metabolizing Enzymes 
Approximately 75% of all exogenous molecules require metabolic transformation into 
active metabolites or waste products before being excreted (Williams et al., 2004). The 
functional units are drug metabolizing enzymes (DMEs) and can be categorized into three 
groups. Phase I and II DMEs are responsible for the direct biotransformation of 
endogenous and exogenous molecules usually by increasing hydrophilicity to ease 
distribution and excretion. The cytochrome P450 superfamily dominates Phase I and are 
found ubiquitously, but concentrated in the intestine, lungs, kidney and most abundantly in 
hepatocytes. Phase II DMEs consist of multiple conjugating enzyme superfamilies such as 
sulfotransferases (SULT), UDP-glucuronosyltransferases (UGT) and glutathione S-
transferases (GST) amongst others. Phase III comprises membrane transport proteins 
belonging to the ATP binding cassette (ABC) family or solute carrier (SLC) family (Xu et 
al., 2005). Together, DMEs build the framework for drug absorption, distribution, 
metabolism and excretion (Sheweita, 2000; Williams et al., 2004). 
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1.5.1 Cytochrome P450s 
CYP enzymes are heme-containing membrane-bound proteins found primarily in the 
endoplasmic reticulum of cells. The common mono-oxygenase is essential for accepting 
an oxygen moiety in a process where electrons, provided by an NADPH-dependent P450 
oxidoreductase (POR), are required for CYP function (Johnson & Stout, 2005). The 
enzymatic goal is to transform lipid-soluble molecules via oxidation into more water-
soluble products. However, the promiscuous substrate-binding nature of CYP enzymes 
mean a single CYP enzyme is capable of multiple reactions utilizing various forms of 
oxidation and reduction (Gad, 2009). The substrate specificity is so broad that ~75% of all 
hepatic xenobiotic metabolism is mediated by CYP enzymes (Williams et al., 2004; 
Wienkers & Heath, 2005). 
There are 57 CYP enzyme genes identified in humans categorized into 18 families 
determined by their amino acid composition. For example, the enzyme CYP3A4 is broken 
down into four components: CYP referring to the cytochrome P450 superfamily, gene 
family #3, subfamily A, and individual isoform #4. CYPs can also be organized with 
respect to the number of drugs or endogenous molecules they are capable of metabolizing. 
Subfamilies CYP1, CYP2 and CYP3 predominately metabolize xenobiotics while most 
other families primarily carry out specific endogenous metabolism of hormones, vitamins 
and bile acids (Gad, 2009). 
Out of the 57 CYP genes, the CYP3A family, CYP2C9, CYP2D6, CYP2C19 and the CYP1A 
family are responsible for ~95% of all CYP mediated drug metabolizing activity (Wienkers 
& Heath, 2005). Specifically, single enzymes CYP3A4 and CYP2C9 are responsible for 
the metabolism of ~43% of all clinically used drugs, thereby making them well-studied in 
the literature and the focus of this work (Zanger & Schwab, 2013). To study human CYP 
enzymes, gene sequence, evolutionary divergence and gene clustering information is used 
to determine the orthologous pairs between human and non-human species. Therefore, 
CYP3A4 and CYP2C9 genes are usually represented as CYP3A2 and CYP2C11 in rat 
models or Cyp3a11 and Cyp2c29/Cyp2c37 in mouse models, respectively (Nelson et al., 
2004; Pan et al., 2016).  
11 
 
1.5.2 Induction & Regulation 
CYP enzyme expression and activity is not only determined by a number of factors 
including genetic polymorphisms, sex and age, but also by continually fluctuating 
bioavailability of substrate (Zanger & Schwab, 2013). Evidence for genetic polymorphisms 
of CYP3A4 are slowly emerging, but remain elusive in comparison to CYP2C9 which has 
multiple single nucleotide polymorphisms (SNPs). The two most common in European 
ancestry are CYP2C9*2 and CYP2C9*3 while CYP2C9*5 is considered rare (Schwarz et 
al., 2008). Warfarin, a known CYP2C9 substrate and anticoagulant drug used in CKD, 
must be administered at a fraction of a normal dose if an individual expresses CYP2C9*2 
or CYP2C9*3 to avoid drug toxicity and adverse effects like bleeding (Gong et al., 2011; 
Klein & Zanger, 2013; Vear et al., 2014). Females tend to have higher levels of CYP3A4 
than males, but age slowly decreases activity in both sexes (Sotaniemi et al., 1995). 
CYP2C9 is relatively static across sexes but increases as juveniles mature (Yang et al., 
2010; Zanger & Schwab, 2013; Vear et al., 2014).  
Substrate bioavailability regulates the expression and activity of CYPs by utilizing a 
plethora of induction pathways. Specifically, CYP3A4 and CYP2C9 can be regulated at 
the transcriptional level by substrate induction of either pregnane X receptor (PXR) or 
constitutive androstane receptor (CAR) (Tirona et al., 2003; Chen et al., 2005). PXR and 
CAR are nuclear receptors containing both a ligand-binding and DNA-binding domain. 
Upon ligand-binding, PXR or CAR translocate into the nucleus to form a heterodimer with 
retinoid X receptor (RXR) before binding to the proximal promotor region of the CYP3A 
or CYP2C gene to upregulate its production (Kliewer et al., 2002). To optimize CYP2C9 
induction, hepatocyte nuclear factor 4 alpha (HNF-4α) is also required to bind to a 
promotor of the CYP2C9 gene (Jover et al., 2009). HNF-4α, along with a list of other 
constitutive elements promote or inhibit CYP3A4 expression in the absence of inducers 
(Honkakoski & Negishi, 2000; Tirona et al., 2003; Zanger & Schwab, 2013). In addition 
to the PXR/CAR induction mechanisms, peroxisome proliferator-activated receptor alpha 
(PPARα) (Thomas et al., 2013), glucocorticoid and vitamin D receptor (VDR) pathways 
(Wang et al., 2013) are slowly being recognized as influencers of CYP3A4 and CYP2C9 
expression (Zanger & Schwab, 2013). More recently, microRNA (miRNA) has shown to 
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influence CYP3A4 directly and indirectly through nuclear receptors PXR, HNF-4α and 
VDR (Pan et al., 2009; Wei et al., 2014). Besides miRNA, mechanisms of post-
transcriptional or post-translational regulation of CYP3A4 and CYP2C9 are largely 
understudied. 
Disease states and associated inflammation are suspected to alter DMEs via changes in 
levels of hormones, regulatory cytokines and other metabolites. Specifically, disease 
modulation of CYP enzymes is usually a downregulation of activity or expression and 
occurs by alteration of basal and inducible transcriptional mechanisms. Inflammation 
activates the NF-κB pathway and inhibits RXR, thus acting as an antagonist for PXR, CAR 
and other transcription factors responsible for CYP induction (Jover et al., 2002; Zhou et 
al., 2006; Morgan, 2009). Models of diabetes mellitus suggest a unique induction of 
CYP3A4 activity and PXR expression by the increased levels of free fatty acids present in 
the serum (Kim & Novak, 2007; Hu et al., 2014). A model of nutritionally induced obesity 
in mice and rats exhibited increased liver triacylglycerol levels as well as decreased liver 
Cyp3a11 and Cyp2c29, although nuclear factors and inflammatory factors were unchanged 
(Yoshinari et al., 2006). The accumulation of normally excreted metabolites is a common 
theme in the suspected cause of disease-associated CYP regulation (Fisher et al., 2009). 
Most drugs are substrates for CYP enzymes (Williams et al., 2004; Wienkers & Heath, 
2005). Pharmaceutically, this creates the dangerous potential for drug interactions. 
Rifampicin is a classic example of a PXR ligand that induces both CYP3A4 and CYP2C9 
expression (Goodwin et al., 1999). A drug co-administered with rifampicin requiring 
CYP3A4 or CYP2C9 metabolism will be extensively metabolized resulting in decreased 
plasma concentration and reduced efficacy (Lynch et al., 2007). In the case of a prodrug 
such as losartan used to treat hypertension, activation will be inhibited if the CYP enzyme 
responsible for the activation is inhibited by a co-administered drug (Lynch et al., 2007). 
This same idea can apply to dietary molecules that influence CYPs. A clinically relevant 
example is the CYP3A4 inhibition by grapefruit juice. When grapefruit juice is co-
administered with drugs dependent on CYP3A4 metabolism, the result is abnormally high 
bioavailability (Bailey et al., 1998). Drug interactions in combination with the multiple 
influences of CYP expression result in high intra- and inter-individual variability in 
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pharmacokinetics. The clinical outcome can be drug toxicity in the form of adverse drug 
reactions (ADR) or drug ineffectiveness. This will be discussed in the context of CKD in 
section 1.5.4. 
1.5.3 Altered Drug Metabolism in CKD 
It is evident that renal drug clearance is hindered by CKD due to a reduced GFR. However, 
it was not until 2009 that non-renal, hepatic drug clearance became clinically relevant for 
kidney disease patients in the Guidance for Industry and not until 2011 that KDIGO 
(Kidney Disease: Improving Global Outcomes) identified non-renal clearance as a usually 
forgotten aspect of pharmacokinetic studies necessary for dose recommendations (Matzke 
et al., 2011). Reviewed by Nolin and colleagues in 2008, eleven drugs known to be 
metabolized by hepatic CYP3A4 showed altered clinical pharmacokinetics in CKD 
patients (Nolin et al., 2008). More recently, eight drugs extensively metabolized by 
CYP3A4 and another three drugs metabolized via CYP2C9 presented reduced non-renal 
clearance in CKD (Ladda & Goralski, 2016). Aliskiren, carvedilol, erythromycin and 
telithromycin are a few CYP3A4 xenobiotic substrates that are commonly administered 
and exhibit altered pharmacokinetics in CKD patients (Ladda & Goralski, 2016). CYP2C9 
is the major metabolizer of warfarin, a drug commonly used in CKD as a blood thinner to 
reduce the risk of stroke or atrial fibrillation associated with cardiovascular diseases. A 
50% reduction in warfarin metabolism in CKD is suspected to be caused by inhibited or 
decreased CYP2C9 (Nolin et al., 2008). This is further supported by Gong and colleagues 
who established that renal function is a determinant of warfarin dosing although warfarin 
is excreted through non-renal pathways suggesting altered DMEs are responsible for 
warfarin pharmacokinetic changes in CKD (Gong et al., 2011). Over 75 drugs exhibit 
reduced non-renal clearance in CKD patients (Yeung et al., 2014). However, it remains 
largely undecided whether levels of DMEs are altered in humans and responsible for the 
altered pharmacokinetics seen in CKD (Nolin, 2015). Early human studies utilized the 
erythromycin breath test to identify impaired CYP3A4 metabolism in ESRD patients 
(Dowling et al., 2003; Nolin et al., 2006). Simply, radiolabeled carbon dioxide end-product 
is measured from the breath of subjects given a known dose of radiolabeled erythromycin, 
a known CYP3A4 specific substrate. When further studies showed DME transporters also 
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influence erythromycin disposition in vitro, the breath test was scrutinized for its indication 
of CYP3A4 activity and blamed for subsequent contradictory results (Frassetto et al., 2007; 
Ladda & Goralski, 2016). Interestingly, using a specific probe drug suggests human 
CYP3A4 activity may not be significantly changed in CKD (Nolin et al., 2009; Thomson 
et al., 2015). Moreover, the most recent meta-analysis study suggested there was only 
modest downregulation of human CYP3A4 in comparison to other CYP enzymes over 
CKD progression (Yoshida et al., 2016). However, extensive animal models of severe 
CKD show severely decreased gene expression, protein expression and enzymatic activity 
of CYP enzymes including CYP3A2 and CYP2C11 as well as Phase II and DME 
transporters (Leblond et al., 2001; Velenosi et al., 2012; Ladda & Goralski, 2016). 
Therefore, the hypothesis remains that altered pharmacokinetics in humans with CKD 
stems from altered DME expression or activity. Research today focuses on the mechanisms 
regulating CYPs in animal models of CKD to further elucidate their function with respect 
to disease. 
1.5.4 Pharmacy & Outcomes in CKD 
Altered CYP function is particularly worrisome in CKD patients because this population 
is elderly, receiving polypharmacy and potentially on dialysis (Sharif-Askari et al., 2014; 
Ladda & Goralski, 2016). These factors increase the risk of a CKD patient experiencing an 
adverse drug event (ADE) or ADR inflicted by a medical intervention, usually by the 
administration of a drug (Bates et al., 1995; Edwards & Aronson, 2000; Munar & Singh, 
2007). ADEs are often due to inappropriate dosing that either enhances the activity of the 
drug and exceeds the intended therapeutic range or fails to meet the therapeutic range 
potentially reducing efficacy and allowing the symptom to persist. 
As there is no cure for CKD, co-morbidities that exist in moderate to severe CKD are 
primarily treated with medications. In total, patients require an average of 7-12 drugs daily 
to manage associated comorbidities and the likely causes of CKD (Talbert, 1994). In a 
study of 512 CKD patients, the risk of ADR was increased when patients were taking over 
8 medications, of which anticoagulant drugs including warfarin caused the highest 
incidence (Sharif-Askari et al., 2014). Secondly, if the patient is on dialysis, a drug’s 
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pharmacokinetics can differ pre- and post-dialysis, further complicating the appropriate 
dose (Velenosi & Urquhart, 2014). Thirdly, most CKD patients are over 65 years of age 
and are likely to be taking additional medications aside from those required to treat kidney 
disease specific comorbidities. As such, the elderly population alone increases the risk of 
ADEs (Sharif-Askari et al., 2014; Davies & O’Mahony, 2015). Thus, dosing 
considerations in each CKD patient requires an individual drug plan and continuous 
monitoring (Corsonello et al., 2005; Matzke et al., 2011). Ultimately, the combination of 
unavoidable polypharmacy and unpredictable drug metabolism is the suspected driver of 
ADEs and ADRs seen in CKD patients (Manley et al., 2005).  
It is therefore important to assess the probable causes of pharmacokinetic alterations in 
CKD. In the following sections, suspected factors contributing to changes in DME 
regulation in CKD will be discussed including the intestinal microbiome and uremia.  
1.6 The Microbiome 
The microbiome is the entire community of bacterial species and their corresponding genes 
that co-exist within the human host gastrointestinal (GI), urogenital and respiratory systems 
as well as on the exterior surfaces of the skin (Cho & Blaser, 2012; Ursell et al., 2012). 
Compared to the human genome, the microbiome is approximately 150 times larger and 
contains many genes that aid in symbiotic functions humans are incapable of carrying out 
on their own (Qin et al., 2010). Bacterial acquisition occurs in infants during and 
immediately following birth (Lloyd-Price et al., 2016). During childhood through to 
adulthood the microbiome is continually shaped in response to a regular diet and 
environmental insults. These are largely associated with geography and race/ethnicity, and 
by two years of age, a “core microbiome” or stable abundance of each major bacterial 
group is established (Huttenhower et al., 2012; Ursell et al., 2014; Lloyd-Price et al., 2016). 
However, the microbiome is far from static and small short-term changes can occur within 
hours of a dietary alteration, largely not affecting the core microbiome (David et al., 2013).  
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1.6.1 Microbiota Methodology 
A decade ago, bacterial species analysis was performed primarily by culture and PCR 
methods limited by the knowledge of individual bacterial species and associated primers. 
However, there are thousands of species residing in a single fecal sample and a large 
proportion of bacteria are unculturable with current techniques making it increasingly 
difficult to assess the bacterial composition or “microbiota” as a complete community 
(Stewart, 2012). Culture-independent methods like Sanger sequencing, although developed 
in the 1970s (Sanger et al., 1977) was a long and laborious process and was rarely utilized 
for sequencing the microbiota (Hiergeist et al., 2015). Around 2005, the first high-
throughput next generation sequencing (NGS) techniques improved the cost and efficiency 
of sequencing, promoting an interest in the microbiome (Gloor et al., 2010; Hiergeist et 
al., 2015). However, in addition to high error rates per-read, the first NGS methods (e.g. 
pyrosequencing) remained expensive and unattainable for many research groups (Gloor et 
al., 2010). Within the last 10 years NGS methods such as Illumina MiSeq have provided 
the ability to assess the microbiota with higher throughput and accuracy at an attainable 
cost (Caporaso et al., 2012; Ramezani et al., 2015). Phylogenetic microarrays are another 
popular method of bacterial sequencing and both NGS and phyloarrays involve a reference 
gene. Usually the 16S small ribosomal subunit rRNA gene is used due to its combination 
of both highly conserved regions used for primer design applicable across all bacterial 
species and the adjacent variable regions utilized for species identification (Janda & 
Abbott, 2007). Unlike phyloarrays that are limited to the known 16S sequences applied to 
the plate, NGS methods allow all 16S genes within a sample to be sequenced regardless of 
previous identification (Vaziri et al., 2012). This is important because unidentified bacteria 
are necessary to understand species richness and diversity indices that are otherwise 
skewed without them.  
Although methodology is constantly improving, gene sequencing results still heavily rely 
on the sequencing method used. In this work, the Illumina MiSeq platform was used to 
perform paired-end sequencing of the 16S rRNA gene focusing on the V4 variable region 
for maximum fecal bacteria coverage (Gloor et al., 2010). Through a process called bridge 
amplification, clusters of DNA are formed on a flow-cell within the sequencer. 
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Sequencing-by-synthesis and dye-terminated primer extension uses fluorescent signals to 
indicate what nucleotide is being added along the amplicon as it is made. Final instrument 
outputs are called reads and after data processing are matched with their most likely 
bacterial sequence. The final product is called an operational taxonomic unit (OTU) and 
generally needs to match the expected bacterial sequence with 97% accuracy (Cho & 
Blaser, 2012; Ursell et al., 2012). OTUs are quantifiable and used to understand the relative 
abundance of each species and diversity indices of a sample. Today, large scale endeavours 
such as the Human Microbiome Project (HMP) and the European project (MetaHIT) 
provide the foundation for bacterial databases (Turnbaugh et al., 2007; Cho & Blaser, 
2012; Huttenhower et al., 2012). 
Due to the vast number of bacteria at varying levels of identification and the large 
proportion yet to be identified, bacterial classification is usually presented as the most 
confirmed tier of the taxonomy ladder. Taxa are arranged in the ecological order of 
kingdom, phylum, class, order, family, genus, species followed by strain if applicable. 
Nomenclature for kingdom through genus taxa are capitalized and only species or strain 
names are italicized (e.g. Escherichia coli; E. coli).  
1.6.2 Gut Microbiota & Host Physiology 
The gut microbiota is the collection of bacteria residing in the lumen or mucosal layer of 
the upper to lower intestine and comprises up to 5000 bacterial species (Nieuwdorp et al., 
2014; Ramezani et al., 2015). Ninety percent of the residential bacteria are dominated by 
phyla Firmicutes and Bacteroidetes and further split into five most prevalent genera 
Bacteroides, Clostridium, Lactobacillus, Escherichia and Bifidobacterium (Nicholson et 
al., 2005; Eckburg et al., 2005; Huttenhower et al., 2012; Goodrich et al., 2014; Mafra & 
Fouque, 2015). It is suggested with some controversy that global intestinal enterotypes or 
common diversity profiles exist in the human population (Arumugam et al., 2011; Knights 
et al., 2014; Moeller & Ochman, 2014). It is agreed however, that different species reside 
in the upper GI tract than those found in the colon and most are obligate anaerobes 
responsible for digestion, immune functions and gut physiology (Eckburg et al., 2005; 
Turnbaugh et al., 2007). Gut bacteria found in the lumen elicit the metabolism of dietary 
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fibres, sugars, alcohols and carbohydrates unable to be metabolized by the host (Nieuwdorp 
et al., 2014). Dietary fibre and some carbohydrates are largely indigestible until bacterial 
fermentation to short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate 
(den Besten et al., 2013). Commensal, or harmless co-existing bacteria, residing in the 
intestinal mucosal layer also support immune function of the host by ultimately inhibiting 
intestinal wall inflammation and subsequent bacterial translocation that could cause 
infection. Some bacteria produce anti-microbial peptides to fend off pathogenic microbes 
while others stimulate immune cell maturation of the host (Belkaid & Hand, 2014; Yip et 
al., 2015). SCFAs produced by bacteria limit the proliferation of effector CD4+ T cells and 
stimulate macrophage suppression of pro-inflammatory molecules (Felizardo et al., 2016). 
Gut bacteria also determine host physiology. Studies utilizing germ-free mice raised in 
sterile environments, show reduced intestinal angiogenesis and ensuing malformed villi 
(Belkaid & Hand, 2014). 
Ties between gut bacteria and host physiology spark questions regarding health and 
disease. Healthy fluctuations in symbiotic gut bacterial abundances are difficult to assess 
as most research focuses on deleterious disease states. In a large cohort of 1106 human 
stool samples, the largest influencers of gut composition were medications, blood 
parameters (e.g. red blood cell count, uric acid, hemoglobin), bowel properties (e.g. Bristol 
stool score, time since previous relief), health and diet (Falony et al., 2016). Dysbiosis is 
the altered bacterial composition associated with a non-infectious disease state (Lloyd-
Price et al., 2016). Many diseases including inflammatory bowel disease, obesity, 
cardiovascular disease, asthma and more recently cancer exhibit dysbiosis (Cho & Blaser, 
2012; Carding et al., 2015; Lloyd-Price et al., 2016). Often the probable cause of dysbiosis 
is indistinguishable from its added clinical manifestations (Vanholder & Glorieux, 2015). 
Luckily, a dignified method of bacterial replacement, usually in the form of fecal microbial 
transplantation (FMT), is used to assess the deleterious effects of diseased bacterial 
compositions by giving dysbiotic bacterial culture to a healthy individual (Manichanh et 
al., 2010). FMT gained popularity after multiple studies showed inducible adiposity when 
intestinal bacteria from obese mice were introduced to lean counterparts (Turnbaugh et al., 
2008). In humans, FMT from healthy, lean individuals into obese individuals improved 
peripheral insulin sensitivity (Vrieze et al., 2012). Even increased susceptibility to 
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atherosclerosis was seen in mice receiving FMT from mice with atherosclerosis-induced 
dysbiosis (Gregory et al., 2015). Thus, the gut microbial community is capable of driving 
disease states. 
1.6.3 Dysbiosis in CKD 
In the 1106 stool sample cohort described above, one of the largest associated factors of 
altered bacterial composition was GFR and thus it comes as no surprise that CKD patients 
exhibit a differing bacterial composition from healthy individuals (Falony et al., 2016). 
Actinobacteria, Firmicutes (especially subphylum Clostridia), and Proteobacteria phyla of 
CKD patients contain changes in specific bacterial genera when assessed using 
phylogenetic microarray (Vaziri et al., 2012). Similar to the microarray results, bacterial 
sequencing showed altered Actinobacteria, Bacteroidetes, Firmicutes (Clostridia), 
Proteobacteria and Verrucomicrobia in ESRD patients (Wong et al., 2014). Unfortunately, 
the only study assessing early renal decline in humans showed bacterial alterations 
occurred solely in the Clostridiales order within the phylum Firmicutes (Barrios et al., 
2015). Rat feces show similar overall composition to those of humans with Actinobacteria, 
Bacteroidetes, Firmicutes, and Proteobacteria among the phyla with the highest 
abundances (Vaziri et al., 2012). When subjected to severe CKD, rat models show 
decreases in both Firmicutes and Bacteroidetes and decreased overall diversity (Vaziri et 
al., 2012). Obesity, a risk factor for CKD, is shown to have decreased levels of 
Bacteroidetes when compared as a proportion to Firmicutes in obese mice (Ley et al., 
2005). A summary of specific gut bacterial alterations in CKD has been reviewed 
(Ramezani et al., 2015). 
Although still unclear, most studies suggest the altered gut composition is a result of CKD 
pathophysiology; however, once established, the altered gut composition has a supportive 
role in CKD progression. CKD patients experience reduced gut motility, dietary changes, 
and a host of pharmaceutical insults which all have explainable impacts on the host gut 
microbial composition. For example, clinicians may recommend the removal of some 
fruits, vegetables or fibre from the diet to combat hyperkalemia which is one contributing 
factor to the reduced abundance of SCFA-producing bacteria in CKD (Wong et al., 2014; 
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Vaziri, 2016). Less obvious is the uremia-associated gut wall inflammation suspected to 
effect bacterial changes in CKD patients. The gut wall integrity is compromised in CKD 
shown by gap-junction alterations likely brought on by inflammation (Lau et al., 2016). 
The gut wall then becomes permeable to uremic toxins including urea, a substrate for 
bacteria with urease activity, which converts urea to ammonia. Ammonia is spontaneously 
transformed into ammonium hydroxide increasing the luminal pH and further damaging 
the gut lumen (Felizardo et al., 2016; Vaziri, 2016). This increase in pH naturally selects 
for species capable of surviving in alkaline environments exhibited by Wong and 
colleagues who demonstrated that bacteria established in ESRD patients favoured a uremic 
environment (Vaziri et al., 2013; Wong et al., 2014). 
Alternatively, manifestations including systemic ramifications of dysbiosis are evident in 
CKD by endotoxin and bacterial DNA fragments found in the bloodstream. Not only would 
a leaky gut lumen explain dysbiosis, but also elucidate the parallel movement of bacteria 
into the blood-stream presented as endotoxemia in CKD and CVD patients (Feroze et al., 
2012; Lau et al., 2016). Appealing to the idea of targeting dysbiosis as a therapy, pro- and 
prebiotics are being investigated as novel dysbiosis treatments (Koppe et al., 2015). A 
recent clinical trial demonstrated positive effects in reducing select uremic toxins in pre-
dialysis CKD patients after a 6 week symbiotic therapy comprised of pre- and probiotics 
(Rossi et al., 2016). Although minor improvements have been suggested in overall CKD 
health, pro- or prebiotic treatment with intent to improve DME function has yet to be 
studied.  
1.6.4 Gut-Derived Uremic Toxins 
Gut-derived uremic toxins are uremic toxins produced by the commensal gut community 
under disease circumstances. An elegant study of germ-free versus conventionally raised 
mice first established that gut bacteria were required to produce host plasma metabolites 
such as indoxyl sulfate (IS) and phenyl sulfate (PS) (Wikoff et al., 2009). Out of the over 
88 uremic toxins identified in CKD, IS and PS are two highly retained, protein-bound, gut-
derived uremic toxins difficult to remove via dialysis (Duranton et al., 2012). Thereafter, 
a feasible connection between uremia and the altered gut microbiota in CKD was formed 
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(Meyer & Hostetter, 2012). In addition to indole and phenol metabolites, other by-products 
of bacterial metabolism include branched-chain fatty acids, SCFAs, ammonia, choline, 
hydrogen sulfide, amines [e.g. trimethylamine-N-oxide (TMAO)] mercaptanes and carbon 
dioxide (Macfarlane & Macfarlane, 2012).  
Indoxyl sulfate begins as dietary tryptophan, transformed into indole by tryptophanase-
possessing gut bacteria including species within the genera Bacteroides, Bifidobacterium, 
Clostridium, Lactobacillus and Parabacteroides (Zhang & Davies, 2016). Indole circulates 
in the plasma until it is shuttled to the liver to be hydroxylated by CYP enzymes and 
sulfated by SULTs before returning to the plasma as indoxyl sulfate (Figure 1.2). Phenyl 
sulfate begins as dietary tyrosine before being sulfated in the liver. Bacteria capable of 
phenol metabolism belong to the Bacteroides, Bifidobacterium, Lactobacillus, 
Enterobacter, and Clostridium genera (Ramezani et al., 2015). Both IS and PS are normally 
excreted via the proximal kidney tubule, but are retained if kidney function is inhibited by 
reduced GFR or CKD-associated inhibition of transporters (Niwa, 2013). In a study of 
bacterial functionality in human ESRD, 12 of 19 microbial families with an increased 
abundance compared to healthy individuals possessed urease activity. Another four 
possessed the ability to produce indole. Two of four families that showed a decrease due 
to ESRD were capable of SCFA production (Wong et al., 2014). This data highlights the 
influence of CKD-induced uremia on the gut through altering the luminal environment and 
selecting for uremic toxin-producing bacteria, ultimately furthering disease progression 
through added uremic toxin production (Figure 1.2). Although biological manifestations of 
each gut-derived uremic toxin are unique and still being elucidated, IS has been of 
particular interest due to its association with overall mortality and multiple comorbidities 
through mechanisms of endothelial dysfunction, renal and cardiac fibrosis, immune 
activation and regulation of various other proteins with functions across all organ systems 
(Barreto et al., 2009b; Vanholder et al., 2014; Ramezani et al., 2015). With uremic toxins 
like IS so heavily linked to CKD progression and comorbidities, therapeutic options like 
pro- and prebiotics are suspected to improve the gut microbiota and systematically reduce 
uremia (Koppe et al., 2015).  
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1.6.5 Metabolomics 
Metabolomics is the study of the entire metabolic profile of a biological matrix utilizing 
high-throughput diagnostic tools such as mass spectrometry (MS) or nuclear magnetic 
resonance (NMR) spectroscopy. Endogenous as well as exogenous metabolites including 
uremic toxins, food metabolites, hormones and other small molecular weight molecules 
can be studied by metabolomics. The field is indispensable for understanding the final 
outputs of cellular processes and provides a picture of cellular mechanisms when analyzed 
alongside gene expression. In this work, metabolomics using MS coupled with advanced 
chromatography tools were used to measure metabolites present in plasma and liver 
homogenates.  
In short, MS involves the ionization of a sample to obtain a mass-to-charge (m/z) ratio at a 
specific retention time unique to each molecule within a sample. To effectively measure 
many metabolites in a complex biological sample, ultra-performance liquid 
chromatography (UPLC) is often used in conjunction with MS to first separate metabolites 
by hydrophobicity before entering the mass spectrometer for ionization. The electrospray 
ionization (ESI) utilized in this work, uses high voltage to form an aerosol from a liquid 
sample. The aerosol is the point at which the molecules of the sample are ionized either in 
positive or negative ionization mode determined by either the addition or removal of a 
hydrogen ion, respectively. Whether a molecule ionizes better in positive or negative mode 
is determined by its molecular composition so generally both modes are used to capture as 
many metabolites as possible. After ionization, the metabolites travel parallel and in the 
center of four quadrupoles where brief alterations in the applied current alters the 
movement of the metabolites travelling through them. The mass of the metabolite 
ultimately determines if it reaches the other end of the quadrupole without being pushed or 
pulled out of the center. Systematically, by altering the window of current applied to the 
quadrupole, each m/z ratio is scanned at high mass accuracy. Following the quadrupole, 
the metabolites enter the collision cell where the parent metabolite may be broken into 
smaller fragments for additional information during identification later in analysis. In this 
work, the MS was run using the MSe Waters method that continuously switches from MS 
to MS/MS data acquisition using a low collision energy for production of parent molecules, 
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and ramping high collision energy, for production of fragments. The parent molecule is 
also called function 1 and the fragmentation data is called function 2. These fragments then 
enter the final time-of-flight (TOF) chamber which further separates the fragments by mass 
but using the time it takes for the ionized molecule to hit a detector after accelerating all 
molecules with the same force. Thus, the measured time required for the metabolite to 
reach the detector is dependent on the mass of the molecule. Ultimately this provides the 
m/z ratio, retention time and fragmentation pattern for each detected metabolite within a 
sample.  
Using this instrument, both targeted and untargeted metabolomics can be conducted. 
Untargeted metabolomics refers to detection and measurement of metabolites within a 
sample without defining metabolites of interest prior to the experiment and is particularly 
useful for understanding the uremic milieu of CKD (Zhao, 2013).  
Due to the large metadata output from metabolomics analysis, complex statistical analysis 
must be utilized (Saccenti et al., 2014). Principle component analysis (PCA) is a common 
multivariate method of displaying samples with respect to their relative metabolite 
compositions in a map-like format for visual verification of differing compositions. PCA 
was also used to visualize patterns of OTUs from the microbiota sequencing data. 
Metabolite features such as the accurate mass, retention time and fragmentation pattern 
captured via MS can be used to identify the metabolite when referenced to an online 
database such as the Human Metabolome Database (HMDB; www.hmdb.ca/) (Wishart et 
al., 2013).  
1.7 Mechanistic DME Regulation in CKD 
The mechanisms suggested for CYP downregulation in CKD are minimally understood, 
but have implicated uremia and uremic toxins, bacterial gut alterations, hormone alterations 
and associated inflammation. The next subsections break down two mechanistic pathways 
of DME alteration in CKD, uremia (section 1.7.1) and dysbiosis (section 1.7.2). 
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1.7.1 Uremia & DMEs 
Since the discovery of uremic toxins, uremia has been considered a top candidate for the 
primary influencer of CYP enzyme manipulation in CKD because multiple mechanisms 
spanning pre-transcription to direct inhibition have been suggested (Velenosi et al., 2014; 
Volpe et al., 2014; Nolin, 2015). In addition to IS and PS, uremia provides a vast number 
of metabolites, many of which are unsuccessfully removed by dialysis and inflict 
pathological effects on other organs including the liver and cardiovascular systems (Niwa, 
2013; Lin et al., 2015). The proposed mechanisms of uremia on DME expression include 
i) reduced nuclear receptor binding and epigenetic histone deacetylation (Velenosi et al., 
2014), ii) NF-κB modulation via inflammatory cytokines or parathyroid hormone (PTH) 
(Michaud et al., 2006, 2008) and iii) direct inhibition by various uremic toxins (Guévin et 
al., 2002; Sun et al., 2004; Barnes et al., 2014; Volpe et al., 2014). However, uremic toxins 
may not be the sole regulator of DMEs. Preliminary studies using intestinal adsorbent AST-
120 in rats with severe CKD show effective removal of uremic toxins without recovery of 
CYP3A2 or CYP2C11 function (Velenosi, 2015). In addition, most of the mechanistic 
studies described above, do not sufficiently provide support for 100% of the observed DME 
alteration.  
1.7.2 Bacteria & DMEs 
The altered gut composition of CKD is suggested to influence DME regulation. Two 
mechanisms are described here. The first is through increased production of uremic toxins. 
In short, increases in uremic toxin-producing bacteria are suspected to increase the load of 
uremic toxins, which are responsible for DME downregulation through mechanisms 
relating to the increased concentration of uremic toxins themselves (see section 1.7.1). 
Thus, removal of uremic-toxin producing bacteria may lessen the strain of uremia in CKD 
(Koppe et al., 2015), but this notion has yet to be evaluated in the context of DME 
alteration.  
It is also possible that bacterial species are required for DME regulation independent of 
uremia. When bacterial species are lost due to CKD, associated dysbiosis may result in 
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faulty DME regulation. This mechanism was first hypothesized after recognizing the 
antibiotic ciprofloxacin diminished the intestinal diversity and impacted CYP expression 
(Toda et al., 2009). However, at the time, it was unclear if this decreased CYP expression 
was due to the drug acting as a direct inhibitor of CYP expression or killing the necessary 
bacteria for CYP function. Shortly thereafter, germ-free mice lacking gut bacteria showed 
reduced drug metabolizing Cyp3a11 and Cyp2c29 expression; however the microbiota was 
recovered upon colonization with gut bacteria from conventionally raised mice (Toda et 
al., 2009; Claus et al., 2011). An extensive gene expression study further showed that 
germ-free mice without gut bacteria have 87% downregulation of Cyp3a11 but unaffected 
Cyp2c29 (Selwyn et al., 2015).  
Displacement of commensal bacteria in a dysbiotic state may remove the normally applied 
suppression of the inflammatory response. Essentially, bacterial SCFAs are implicated 
with many immunomodulatory effects including T cell inactivation, downregulation of 
TNFα/β, IL-6 and IL-1β, and inhibition of macrophage NF-κB nuclear translocation 
required for its activation (Lührs et al., 2002). As previously demonstrated, inflammation 
through activation of the NF-κB pathway can block DME expression via inducible PXR 
regulation (Gu et al., 2006). Mechanistically, molecules derived from bacteria like 
lithocholic acid (LCA) promote PXR activation responsible for CYP induction (Staudinger 
et al., 2001; Toda et al., 2009). Thus, one of the ways dysbiosis might affect drug 
metabolism is through loss of beneficial bacteria or beneficial molecules produced by 
bacteria required for DME induction.  
It is important to note however, that dysbiosis is suspected to be caused by deleterious 
effects of uremic toxins on the gut wall. This highlights the proposed positive feedback 
manifestation of dysbiosis and uremia in CKD (Figure 1.2) (Vanholder & Glorieux, 2015). 
Assessment of both dysbiosis and uremia along the progression of CKD is suspected to 
shed light onto which factor may be primarily influential in DME alteration.  
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Figure 1.2. Pathophysiological summary of uremia and dysbiosis in CKD. A) Pathway of 
uremic toxins: IS, PS, p-cresol sulfate and TMAO. B) The cyclic gut-kidney relationship. 
Uremic toxins and associated inflammation are suspected to impede the integrity of the gut 
lumen allowing urea and other toxins to cross the leaky intestinal barrier and increase the 
luminal pH promoting growth of uremic-toxin-producing bacteria and overall dysbiosis. 
This promotes further production of uremic toxins associated with disease progression and 
CKD comorbidities. Images were modified from Servier Medical Art 
(www.servier.co.uk/medical-art-gallery).  
A 
B 
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1.8 Hypothesis & Objectives 
1.8.1 Rationale 
Currently the literature demonstrates non-renal drug clearance is altered in CKD. It is less 
clear why proteins such as DMEs are altered. Suggested mechanisms include alterations of 
the gut microbiota or uremic toxins. Thus, studies are needed to link gut-derived uremic 
toxins (e.g. IS) and gut bacteria with DMEs. Human DME orthologs have been studied in 
rat models of CKD but these studies focus only on severe or late-stage CKD leaving a gap 
in our understanding of when CKD factors and DME expression changes (Leblond et al., 
2001; Velenosi et al., 2012; Ladda & Goralski, 2016). Additionally, very few studies have 
looked at both bacterial alterations and metabolomics within one CKD cohort, none of 
which have focused on DMEs (Ursell et al., 2014; Nallu et al., 2016). To our knowledge, 
no studies have assessed the effect of CKD on hepatic DMEs over disease progression in 
attempt to understand when uremic toxins are changing relative to DME alterations. 
Additionally, this thesis will be the first to encompass metabolomics, 16S bacterial 
sequencing and DME analysis over CKD progression.  
1.8.2 Hypothesis & Objectives 
Although both the uremic and microbial environments are altered in CKD patients, their 
roles in DME regulation remain unclear. The pathophysiological factors of uremia and 
dysbiosis have never been tested temporally over the progression of CKD. The basic 
principle of causality dictates that for a factor (e.g. uremia or dysbiosis) to be causative, it 
must exist or apply the effect before the outcome (e.g. DME regulation) in time (Otero et 
al., 2014). Elucidating the series of events that occur over CKD progression may provide 
support for current hypotheses, which suggest uremic toxins or bacterial alterations are 
causal factors in DME regulation. Alternatively, results may fail to support current 
hypotheses by finding DME changes occur before the suspected causal factors. Thus, this 
thesis aims to reveal the timing in which each pathophysiological factor changes in the 
attempt to support the hypothesis that uremic toxins and/or bacterial alterations are 
mechanistically involved in the regulation of DMEs in CKD. Specifically, we aim to 
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characterize plasma and liver uremic toxins, the gut microbial composition and DME 
fluctuation over the progression of an adenine-fed rat model of CKD. We hypothesize that 
adenine-induced CKD will cause uremia and gut microbial changes detectable prior to the 
anticipated downregulation of CYP3A2 and CYP2C11 DMEs.  
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Chapter 2  
2 Materials & Methods 
2.1 Animal Model & Study Design 
Animal work was approved by the Western University Animal Care Committee and 
experiments were conducted in accordance with the Canadian Council on Animal Care 
(Appendix A). Sixty-six male Wistar rats (initially 150g) were obtained from Charles River 
Laboratories, Inc. (Wilmington, MA) and randomized into six groups defined by time of 
sacrifice (day 0, 3, 7, 14, 28 and 42). Each time point consists of a minimum six control 
and six CKD rats along with six control rats on day 0. Rats were housed in a conventional 
animal care facility with a 12h light cycle. Rats were paired with a same-group cage mate 
to minimize coprophagy alterations of the gut microbiota. All rats were acclimated for 
seven days prior to starting either 0.5% adenine supplemented Teklad 22/5 Rodent Diet 
(Harlan Laboratories Inc., Madison, WI) for CKD rats or standard chow pair fed to match 
caloric intake for control rats (Prolab® RMH 3000, LabDiet, St. Louis, MO). Water was 
provided ad libitum to both groups. Body weights were monitored daily (Table 3.1) until 
sacrifice via isoflurane anesthetization followed by decapitation. Blood was collected in 
heparinized tubes. Liver was snap-frozen in liquid nitrogen. Caecal samples were obtained 
on a sterile, single culture swab (BD, Sparks, MD) touched to an open incision at the 
enlarged proximal end of the rat caecum. All samples were stored at -80°C until further 
analysis excluding the right kidneys which were stored in 10% formalin until histological 
embedding.  
2.2 Disease Markers & Histology 
Conventional CKD markers urea (mmol/L) and creatinine (µmol/L) were measured in rat 
plasma using standard methods by the Pathology and Laboratory Medicine group (PaLM, 
London, ON; www.lhsc.on.ca/palm/). Kidney tissue and histological images were prepared 
as previously described (Feere et al., 2015). Briefly, kidneys were fixed in 10% formalin 
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(Anachemia Canada Co., Montreal, QC) before undergoing tissue slide preparation at the 
Department of Pathology (Western University, ON). Light microscopy and photographs of 
prepared haematoxylin and eosin (H&E) stained slides were obtained under identical 
exposure, saturation and contrast on a Leica DM1000 light microscope paired with a Leica 
DFC295 colour camera and Leica Application Suite v3.8.0 software.  
2.3 Real-Time PCR 
In preparation for quantitative (real-time) PCR, total mRNA was extracted from rat liver 
using TRIzol reagent (Life Technologies, Burlington, ON) following the manufacturers 
protocol before quantification and purity testing using a Nanodrop 2000 
(ThermoScientific, West Palm Beach, FL). One µg of total RNA underwent reverse 
transcription (Bio-Rad C1000) for cDNA synthesis using qScript cDNA Supermix (Quanta 
Biosciences, Gaithersburg, MD). Amplified cDNA was diluted 1:40 before running 5µL 
in triplicate on a 384-well plate with 7µL mastermix containing primers and PerfeCTa 
SYBR green fastmix (Quanta Biosciences, Gaithersburg, MD). Rat primers for CYP3A2 
(forward)     [5’-GCTCTTGATGCATGGTTAAAGATTTG-3’] and (reverse) [5’-
ATCACA GACCTTGCCAACTCCTT-3’] and CYP2C11 (forward) [5’-CCCTGAG 
GACTTTTGGGATGGGC-3’] and (reverse) [5’-AGGGGCACCTTTGCTCTTCCTC-3’] 
(Invitrogen) were previously validated by cycle threshold (Ct) and melt-curve analysis 
(Velenosi et al., 2014). β-Actin was used as the housekeeping gene (forward) [5’-
ACGAGGCCCAGAGCAAGA-3’] and (reverse) [5’-TTGGTTACAATGCCGTGTTCA-
3’], samples were run on a Bio-Rad CFX384 Real-Time System (Hercules, CA, USA) and 
relative RNA expression was assessed through the ΔΔCt method (Livak & Schmittgen, 
2001; Rao et al., 2013).  
2.4 Western Blotting 
2.4.1 Microsomal Isolation & BCA Assay 
Hepatic microsomal fractions were prepared by differential centrifugation followed by 
Pierce BCA assay as previously described (Feere et al., 2015). Briefly, approximately 1/6 
of each rat liver was homogenized using a T10 Basic Ultra-TURRAX (Sigma Aldrich, St. 
31 
 
Louis, MO) on ice in 1mL of buffer [1.15% KCl + 1mM ethylenediaminetetraacetic acid 
(EDTA)] for 5 min. Samples were centrifuged at 4°C in an ultracentrifuge (Beckman 
Coulter Optima L-90K, Fullerton, CA), first at 9000×g for 20 min to collect the supernatant 
which was further spun at 105,000×g for 1 hour. Total microsomal pellet was suspended 
in 500µL storage buffer (0.1M potassium phosphate buffer + 20% glycerol, pH=7.4) and 
subsequently separated into two aliquots of approximately equal amounts before storing at 
-80°C. A Pierce BCA Protein Assay kit (Thermo Scientific) was used to assess total protein 
content from diluted microsomal fractions (1:100) in a 96-well plate. Concentrations of 
1000, 500, 250, 125, 62.5, 0 µg/mL protein standard (Sigma Aldrich) provided a sufficient 
standard curve to measure all samples by chemiluminescence on a plate reader 
(SpectraMax-M5). The original microsomal fraction was aliquoted to 5µg/µL total protein 
and stored at -80°C until western blot analysis. 
2.4.2 Gel Electrophoresis & Blotting 
Western blot analysis was performed as previously depicted with minor alterations (Feere 
et al., 2015). Electrophoresis was optimized on a 15-well 10% polyacrylamide resolving 
gel with 4% stacking gel containing 0.1% sodium dodecyl sulfate (SDS) and polymerized 
using ammonium persulfate and tetramethylethylenediamine (TEMED) (Bio Basic Inc, 
Markham, ON). A total of 4µL loading volume contained 4.8µg of protein per well. The 
samples were diluted in sample buffer (10% SDS, 26% glycerol and 0.5% bromophenol 
blue) and reduced with beta-mercaptoethanol at 80°C for 20 min. The gel was run at 60V 
for 20 min followed by 120V for 45mins in Bio-Rad Running Buffer. Protein was 
transferred to a nitrocellulose membrane for 1.5 hours with 120V in Bio-Rad Transfer 
Buffer. The membrane was washed with PBS + 0.1% tween (PBS-T) before blocking with 
PBS-T + 5% skim milk powder + 0.6% bovine serum albumin (BSA) for 1 hour followed 
by three washes of PBS-T. Primary CYP3A2 rabbit anti-rat antibodies (Millipore, 
Temecula, CA) were diluted 1:8000 with PBS-T + 0.6% BSA. CYP2C11 mouse anti-rat 
antibody (Millipore, Temecula, CA) was diluted 1:5000 with PBS-T + 5% skim milk 
powder. β-Actin housekeeping primary antibody, conjugated to horseradish peroxidase 
(HRP), was made in mouse (Sigma Aldrich), diluted 1:50000 with PBS-T + 0.6% BSA and 
made fresh before each use. After 4°C overnight incubation with primary antibody and 
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subsequent PBS-T washes, secondary antibody (rabbit or mouse) linked to HRP (Santa 
Cruz Biotechnology Inc., Santa Cruz, CA) at 1:10000 dilution in PBS-T + 0.6% BSA were 
incubated with the blots for no longer than 1 hour. Imaging was performed on the Bio-Rad 
VersaDoc Imaging System (Hercules, CA) and accompanying QuantityOne (v4.6.3) 
software after final washing steps and 1 min incubation of 1 mL chemiluminescent agent 
Luminata Forte western blot HRP substrate (Millipore, Billerica, MA). After imaging of 
CYP3A2, the blot was washed, stripped of protein (Restore Western Blot Stripping Buffer, 
ThermoScientific, Rockford, IL) and washed with PBS-T once more before the application 
of the β-Actin or CYP2C11 primary antibody before repeating the washes and imaging 
steps. Densitometry data was normalized to β-actin, presented as a percent of day 0 control 
samples and standardized across blots by a communal pooled sample run on every blot. 
Western blot analysis was completed in duplicate for both CYP3A2 and CYP2C11. 
2.5 Enzymatic Activity 
Enzymatic activity was analyzed by incubating microsomal fractions with testosterone, a 
known substrate of CYP3A2 and CYP2C11 (Chovan et al., 2007). The respective products 
6βOH-testosterone and 16αOH-testosterone were measured via mass spectrometry (MS) 
in a 96-well plate assay adapted from (Feere et al., 2015). In a final volume of 75µL, 
0.2mg/mL microsomal protein and reaction buffer (50 mM potassium phosphate with 2 
mM MgCl2 pH 7.4) was incubated with 1µL testosterone (Steraloids Inc., Newport, RI) 
substrate at concentrations of 12.5, 25, 75, 200 and 400µM for 10 min at 37°C. Reaction 
volume is completed by incubation with 1mM NADPH (Sigma Aldrich) and shaken at 
37°C for exactly 20 min before sequestration using 225µL ice-cold acetonitrile with 
80ng/mL flurazepam as an internal standard (Cerilliant, Round Rock, TX). Plates were 
shaken, centrifuged at 4000×g for 10 min, supernatant diluted 1 in 5 with milliQ water and 
stored at 4°C no longer than 24 hours until analysis. Enzymatic products were separated 
on an ultra-performance liquid chromatography (UPLC) Phenomenex Kinetex phenyl-
hexyl column (1.7µm particle size, 50mm × 2.1 mm) maintained at 40°C in a Waters 
ACQUITY UPLC I-Class System (Milford, MA). Mobile phase flow was set to 0.5 ml/min 
and consisted of UPLC-grade water (A) and acetonitrile (B) both containing 0.1% formic 
acid with a gradient as follows: 0–0.5 mins, 25% B; 0.5–2 mins 25–35% B; 2–2.5 mins 
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35–80% B; 2.5–3.5 mins held at 80% B; 3.5 mins 25% B. Analytes were detected using 
quadrupole time-of-flight mass spectrometry (UPLC-QTof/MS) on a Waters XevoTM G2S-
QTof/MS and Waters ACQUITY I-Class UPLC with parameters as previously described 
(Feere et al., 2015). The positive mode mass-to-charge ratio (m/z) for 6βOH-testosterone 
and 16αOH-testosterone (m/z = 305.2117) were quantified using standard curves of 
purchased 6βOH-testosterone (0.04–50μM) and 16αOH-testosterone (0.09–100μM) 
(Steraloids Inc., Newport, RI) using QuanLynx v4.1 software. Michaelis-Menten curves 
generated with GraphPad Prism (v5.0 for Windows; GraphPad Software Inc., San Diego, 
CA) were used to find the maximum enzymatic reaction rate (Vmax), Michaelis-Menten 
constant (Km) and average intrinsic clearance (Vmax/Km) for each group. 
2.6 Untargeted Metabolomics 
2.6.1 Sample & Batch Preparation 
Plasma and liver biological matrices each run on two different chromatography columns 
totaling four metabolomics runs. The first column, a Waters ACQUITY UPLC HSS T3 
(1.8μm particle size, 100 mm × 2.1 mm) reverse-phase liquid chromatography (RPLC) 
column best encompasses hydrophobic molecules while the second hydrophilic interaction 
liquid chromatography (HILIC) column, a Waters ACQUITY BEH Amide (1.7μm particle 
size, 100 mm × 2.1 mm), best separates hydrophilic molecules. Plasma and liver samples 
were prepared as previously described (Velenosi et al., 2016) by adding 3:1 ice-cold 
acetonitrile with 2.5µM chlorpropamide internal standard (Sigma Aldrich) to 100µL of rat 
plasma or 200mg ± 5mg homogenized liver sample. Samples were vortexed, incubated at 
-20°C for 20 min then centrifuged at 14,000×g for 5 min. Supernatant was either diluted 
1:5 in water for RPLC or directly injected for HILIC. Sample injection order was 
randomized and a quality control sample made from pooled samples was run every ten 
injections to monitor instrument drift. All samples were run in a single batch for each 
biological matrix and column.  
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2.6.2 Chromatography & Mass Spectrometry 
Both RPLC and HILIC columns were maintained as previously stated (Velenosi et al., 
2016) at 45°C and mobile phase flow set to 0.45 ml/min consisting of UPLC-grade water 
(A) and acetonitrile (B), both containing 0.1% formic acid. A gradient of 0-2 min 60% B; 
2-6 min 85% B; 6-8 min 99% B; 8-10 min 1% B was used. The HILIC column followed a 
gradient of 0–0.5 mins 99% B; 0.5–6 mins 99–50% B; 6–8 mins 50–30% B; 8–8.5 mins 
30–99% B. Samples were run separately in succession for both positive and negative 
electrospray ionization (ESI) modes on the UPLC-QTof/MS instrument described in 
section 2.5. Mass spectrometer method consisted of capillary voltage 2kV, cone voltage 
40V, source temperature at 150°C, desolvation gas flow 1200L/h at 600°C, and cone gas 
flow 50L/h. Data acquisition was conducted in centroid mode using the MSe method as 
described in section 1.6.5, with 0.05s scan time over a range of 50-1200 m/z with collision 
energy of 0V for MS (function 1) and ramped from 15V-50V for MS/MS (function 2) 
fragmentation. For mass accuracy, lockspray solution leucine-enkephalin (500ng/mL) was 
used as the lockmass and set at a flow rate of 10µL/min, measured every 10s and averaged 
over 3 scans. Data was collected by MassLynx v4.1 software (Waters). In anticipation of 
detecting previously identified uremic toxins IS, PS and 4-ethylphenyl sulfate, a standard 
curve of these metabolites was added to the front and back of both RPLC runs in plasma 
and liver.   
2.6.3 Data Processing 
Data processing for each run and ESI mode was performed separately in R studio (v3.2.3). 
MassLynx data files were converted from raw to mzData files using convert.waters.raw 
package v1.0 (github.com/stanstrup/convert.waters.raw). Pooled samples were used to find 
the optimal peak picking parameters, retention time corrections and grouping parameters 
simultaneously with the isotopologue parameter optimization (IPO) package v1.0.0 
(github.com/rietho/IPO/blob/master/vignettes/IPO.Rmd). Minimum peak width ranged 
from 2 to 5 seconds, maximum peak width ranged from 10 to 20 seconds and a static ppm 
of 15 were used as starting parameters for the IPO process. The resulting IPO parameters 
unique for each mode were inputted into the XCMS package v1.50.1 (Smith et al., 2006) 
to pick appropriate peaks, integrate the area under the curve and replace zero values for all 
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samples within the dataset. The CAMERA package v1.32.0 was used to annotate possible 
isotopes and adducts (Kuhl et al., 2012). XCMS and CAMERA packages were used to 
integrate positive and negative ESI modes before normalizing to internal standard 
chlorpropamide and applying a threshold of 30% variability of the quality control. Through 
an in-house R script positive and negative modes were combined to make one dataset ready 
for statistical software with masses identified in both modes retained in the mode with 
greater intensity (Urquhart Laboratory, unpublished). 
2.6.4 Metabolite Identification 
The accurate monoisotopic mass (m/z) and fragmentation spectrum of each metabolite was 
used to identify potential metabolite matches within the METLIN, MassBank or Human 
Metabolome Database (HMDB) (Wishart et al., 2013). This was carried out by first 
searching the parent m/z ratio in the corresponding ionization mode across all possible 
adducts with a molecular weight tolerance of ±0.01Da. The MOL file for each suspected 
metabolite was downloaded from the HMDB website and uploaded using MassFragment, 
a MassLynx software add-on, to compare expected fragmentation patterns with the 
experimental fragmentation pattern. Fragmentation profiles of metabolites representing the 
most experimental fragments were purchased for identity confirmation. 
A categorical system of metabolite identification has been adapted from previously defined 
levels 1 through 4 (Salek et al., 2013). To confirm a suspected metabolite’s identity, a 
purchased standard was run and compared to a sample known to have the unidentified 
signal. If the retention time, accurate mass and fragmentation pattern matched across the 
experimental sample and purchased standard, it was considered “level 1 identified”. Level 
2 identified metabolites exhibited HMDB and METLIN database matches with delta ≤ 
5ppm and conformation to at least one of the following criteria: a matching online database 
fragmentation spectrum, or matching m/z ratio in a publication where it was similarly 
identified. Level 2 identification is typically used when analytical standards are unavailable 
or the cost prohibits level 1 identification. Level 3 identified metabolites required only a 
HMDB and METLIN match with delta ≤ 5ppm. Metabolites with multiple matches, zero 
matches or deltas ≥ 5ppm were considered unknown. 
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Metabolite standards were obtained as follows: indoxyl sulfate from Gold Biotechnology 
(Olivette, MO), phenyl sulfate and 4-ethyl phenyl sulfate were synthesized as previously 
described (Velenosi et al., 2016), allantoin, L-carnitine, 2,8-dihydroxyadenine and equol 
4/7 glucuronide were purchased from Toronto Research Chemicals (Toronto, ON), 
creatinine from Sigma Aldrich and pantothenic acid from Supelco (Bellefonte, PA). 
2.7 Gut Microbial Sequencing 
2.7.1 Illumina Sequencing 
DNA was extracted from caecum swabs using the PowerSoil-96 Well DNA isolation kit 
from MoBio using convenience modifications of the Earth Microbiome Project protocol 
(Gilbert et al., 2014). Unique barcoded primers named 515F and 806R (Caporaso et al., 
2011; Gilbert et al., 2014) amplified the V4 variable region of the 16S rRNA gene. A total 
of 12 forward and 24 reverse primers barcodes were used to provide 288 unique primer 
combinations. The primers are as follows: forward primer [5’-ACACTCTTT 
CCCTACACGACGCTCTTCCGATCTnnnn(8)GTGCCAGCMGCCGCGGTAA-3’] and 
reverse primer [5’-CGGTCTCGGCATTCCTGCTGAACGCTCTTCCGATCTnnnn 
(8)GGACTACHVGGGTWTCTAAT-3’] where the 5’ end is the Illumina adaptor 
sequence, the nnnn indicates four random nucleotides, (8) represents one of the 36 
barcoded sequences eight nucleotides in length and the 3’ end is the primer region for V4 
(Supplementary Table 1. Appendix B) (Gloor et al., 2010). Amplification was carried out 
in 42µL total volume with 20µL primer mix (3.2pmol/µL per primer), 20µL GoTaq Hot 
Start Mastermix (Thermo Scientific) and 2µL template DNA then run for 2 min at 95°C 
followed by 25 cycles of 1 min at 95°C; 1 min at 52°C and 1 min at 72°C excluding a final 
elongation. Barcoded PCR products were quantified with a Qubit dsDNA assay kit on a 
Qubit 2.0 (Life Technologies), normalized by amount of DNA, pooled then purified with 
a PCR clean-up column. The cleaned DNA is amplified once more with primers OLJ139 
[5’AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGA3’] and 
OLJ140 [5’CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATT 
CCTGCTGAAC3’] (Majerczyk et al., 2010) before paired-end, high-throughput 
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sequencing on the Illumina MiSeq platform at the London Regional Genomics Centre 
(LRGC, lrgc.ca, London, ON).  
2.7.2 Data Processing 
Paired reads, each 220bp long were processed with the Illumina_SOP protocol accessed 
through Github with minor convenience revisions (https://github.com/ggloor/miseq_bin). 
After demultiplexing, raw reads were first overlapped with a minimum 30 nucleotides 
using Pandaseq (v2.5) (Masella et al., 2012) then filtered with in-house Perl and UNIX 
scripts to ensure exact barcode matching and primer matching with up to two allowable 
mismatches (Gloor et al., 2010). OTUs were clustered using the uSearch (v7.0.1090) script 
(Edgar, 2010) at 97% identity and the most abundant sequence was applied for annotation 
via the mothur script (Schloss et al., 2009) to search the Silva 16S rRNA gene reference 
database (Silva.nr_v119) (Quast et al., 2013; Yilmaz et al., 2014). In mothur, a bootstrap 
cut-off of 70% was used for taxonomical identification and redundancy. A total of 1199 
OTUs were retained across all samples (Supplementary Table 2. Appendix B). Due to study 
time-period differences, only days 3, 14, 28 and 42 could be used for sequencing analysis. 
In R studio (v3.2.3) the zCompositions (v1.0.3-1) package (Martín-Fernández et al., 2003) 
was used for zero-replacement before data was centre-log ratio (clr) transformed for 
compatibility with downstream univariate and multivariate statistics (Gloor & Reid, 2016; 
Gloor et al., 2016b).  
2.8 Statistical Analysis 
2.8.1 Disease Markers, Real-Time PCR, Western Blotting & 
Enzymatic Activity Assay 
DME measurements and disease markers urea and creatinine are presented as mean ± SEM 
and analyzed by 2-way ANOVA paired with Sidak’s multiple comparisons test. *p < 0.05 
compared to matching day control indicates significance.  
2.8.2 Untargeted Metabolomics 
Principal component analysis (PCA) was used to evaluate the initial separation between 
CKD and control over time for each of the four analytical runs using MassLynx software 
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and the EZInfo v2.0 package (Umetrics, Umeå, Sweden). Placement of each sample within 
a PCA plot is determined by the entire detectable metabolite composition within each 
sample with relation to all other samples. Samples within close proximity are considered 
“clustered” and represent samples with similar compositions. Data for each of the four runs 
was Pareto scaled to remove emphasis on metabolites with large magnitude of variance. 
Outliers were removed utilizing a Hotelling’s analysis with a maximum allowable T2 range 
of 35 (Wiklund, 2008). Pooled samples are confirmed to show little variance and a clear 
separation is identified between control and condition before applying statistics. Each 
statistical method: multivariate, univariate and correlations to each DME, was performed 
independently on the same metabolomics dataset for each of the four runs with the aim to 
isolate metabolites related to CYP alterations. Each of the 1] multivariate, 2] univariate and 
3] correlation analyses are described below. 
1] Multivariate analysis was performed on all four runs, on all 5 days in comparison with 
same day control. EZInfo was used to generate orthogonal partial least squares discriminant 
analysis (OPLS-DA) of the original PCA (Figure 2.1). OPLS-DA, unlike PCA, is a 
supervised comparison between known groups. To assess multivariate OPLS-DA 
sufficiency, each comparison received goodness of fit values R2 and Q2. R2 is the goodness 
of fit estimated for the model and Q2 is the level of prediction accuracy the model infers if 
the experiment were to be repeated. The values are dependent and thus can be expressed 
as a ratio (R2/Q2) with the expectation that R2/Q2 < 2 or Q2 > 0.5 (Triba et al., 2015). The 
metabolites characteristic of treatment were then plotted as an S-plot with axis of 
“p(corr)[1]” representing the treatment difference and “p[1]” representing the magnitude 
of the metabolite’s influence. Strict thresholds were applied (VIP > 0.8; p(corr)[1] > 0.4 or 
< -0.4) by finding the variable importance in projection (VIP) and the p(corr)[1] axis as a 
general measure of magnitude and difference between treatments (Farrés et al., 2015) 
(Figure 2.1). Only metabolites that met or exceeded the S-plot thresholds on two or more 
consecutive time points were retained for comparison with univariate and correlative 
analyses. 
2] Univariate analysis on the original metabolomics datasets were used to assess the 
relative concentration of each metabolite over time and course of the disease. Open access 
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online software MetaboAnalyst 3.0 was used to perform a p-value corrected (FDR = 0.05) 
independent 2-way ANOVA on each metabolite via the “Time Series” and “Two-factor 
independent samples” applications (Wishart et al., 2013). No additional data filtering, 
normalization or transformation was performed. Pareto scaling was applied for 
consistency. Significance (p<0.05) was required for both “Time” and “Disease” to retain 
the metabolite for comparison with multivariate and correlative analyses.  
3] Spearman correlations were conducted between each metabolite and the mRNA, protein 
or enzymatic activity levels of each enzyme. Spearman correlation analysis of 
metabolomics results have been conducted in the past to compare metabolites to other 
metabolites (Camacho et al., 2005), metabolites to bacterial abundances (Theriot et al., 
2014; McMillan et al., 2015), and metabolites to gene expression (Bartel et al., 2015; 
Auslander et al., 2016). Original processed metabolomics dataset for each run was matched 
by sample to the corresponding DME dataset and a correlation coefficient (r) obtained 
before comparison to the final multivariate and univariate subsets. R-values were manually 
filtered with high stringency (r > 0.65 or r < -0.65) since more than 50% of the dataset 
satisfied p<0.0001. After filtering, correlation analysis provided the smallest subset of the 
three analysis methods. Metabolites on this list that did not also satisfy univariate analysis 
were removed from the correlation subset. Metabolites that did not satisfy multivariate 
analysis are indicated but retained to capture biologically relevant changes independent of 
magnitude.  
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Figure 2.1. Example of multivariate analysis workflow utilizing OPLS-DA and S-plots. A 
PCA is made using EZInfo software (1), comparisons are chosen for OPLS-DA, an OPLS-
DA plot of sample distribution is made and R2 and Q2 thresholds are applied (2). Successful 
OPLS-DA plots are further analyzed by observing metabolite contributions towards either 
condition by S-plot (3) where VIP and p(corr)[1] thresholds are applied. From the S-plot, 
a list of m/z ratios and retention times (4) in addition to fragmentation pattern are searched 
within online databases such as HMDB in attempt to identify the metabolite. 
 
41 
 
2.8.3 Caecal Microbiota 
Multivariate PCA was performed in EZInfo as described for untargeted metabolomics 
except no scaling was utilized to emphasize large variations. Although applied infrequently 
in the microbiology field (Hong et al., 2011; Stewart et al., 2015), R2 and Q2 values are 
important for understanding the variability in the PCA and were calculated for consistency 
with metabolomics analysis. To obtain univariate differences between CKD and control 
groups, the effect size and overlap for each bacterial taxonomic group was calculated for 
each time point individually using the R package ALDEx2 (v1.2.0) 
(bioconductor.org/packages/release/bioc/html/ALDEx2.html) (Fernandes et al., 2014; 
Gloor et al., 2016a). Severe thresholds were applied to both effect size (> 1.5 or < -1.5) 
and overlap (< 6.5%) for each bacterial abundance (Macklaim et al., 2013; Halsey et al., 
2015; Gloor et al., 2016a). OTUs that met or exceeded the thresholds were graphed and 
significance was defined as satisfying the effect size and overlap thresholds with 95% 
confidence. Where applicable, genera were manually searched for species and strain 
information by Targeted Loci Nucleotide BLAST application through NCBI 
(blast.ncbi.nlm.nih.gov/Blast.cgi).  
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Chapter 3  
3 Results 
3.1 Model Validation 
First, I validated the adenine-fed CKD model by measuring plasma CKD markers urea and 
creatinine alongside kidney histological analysis across all time points. CKD markers urea 
and creatinine both showed significant increase in CKD rat plasma by day 14 (Figure 
3.1.A-B). This increase continued to a 9-fold and 11-fold difference between CKD and 
control for urea and creatinine, respectively, on day 42. Kidney histology showed enlarged 
tubules, inflammatory cells and fibrosis by day 14 through to day 42 (Figure 3.1.C-H). 
Animal weights did not change between groups (Table 3.1).  
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Figure 3.1. Assessment of CKD in Wistar rats orally administered 0.5% adenine over 42 
days. (A) Plasma urea (mM) and (B) serum creatinine (µM) concentrations of control and 
CKD rats presented as mean ± SEM. *p < 0.05 when compared to matching day control; n 
≥ 6. H&E stained rat kidney sections from day 42 control (C) and CKD days 3 (D), 7 (E), 
14 (F), 28 (G) and 42 (H). Arrows indicate enlarged nephron tubules and areas of fluid 
retention. Inflammatory cells and areas of atrophy are evident on days 14, 28 and 42.  
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Table 3.1. Weight in grams of control and CKD rats over 42 days. 
 Control CKD 
Weight (g) 
Day 0 206.5 ± 1.4   (n=41) 207.1 ± 1.8   (n=36) 
Day 3 188.6 ± 1.1   (n=41) 186.1 ± 1.5   (n=36) 
Day 7 201.0 ± 1.5   (n=24) 202.4 ± 1.9   (n=26) 
Day 14 227.3 ± 2.0   (n=18) 227.9 ± 3.3   (n=19) 
Day 28 257.3 ± 2.6   (n=12) 258.3 ± 5.0   (n=13) 
Day 42 274.5 ± 8.4   (n=6) 254.7 ± 12.7   (n=7) 
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3.2 Hepatic CYP3A2 & CYP2C11 mRNA Expression over 
CKD Progression 
Having confirmed the adenine-fed rats were developing CKD, the mRNA expression of 
DMEs CYP3A2 and CYP2C11 were assessed in the liver. CYP3A2 mRNA expression was 
minimally decreased on day 3, recovered on day 7, then declined substantially by day 14 
(-83%, p<0.001) which persisted to day 42 (-99%, p<0.001) (Figure 3.2.A). CYP2C11 
mRNA expression was unchanged on day 3 but largely increased in the control group on 
day 7 leaving CKD rats well below normal (-76%, p<0.001) (Figure 3.2.B). On day 14 (-
84%, p<0.001), day 28 (-96%, p<0.001), and day 42 (-98%, p<0.001) the CKD CYP2C11 
mRNA expression remained low in comparison to control.  
3.3 Hepatic CYP3A2 & CYP2C11 Protein Expression over 
CKD Progression 
To ascertain whether protein expression was changed with respect to mRNA expression, 
CYP3A2 and CYP2C11 protein quantification was carried out by western blotting. 
Decreases in CYP3A2 protein levels were seen on day 14 (-63%, p<0.001), day 28 (-86%, 
p<0.001) and day 42 (-85%, p<0.01) (Figure 3.2.C). CYP2C11 protein quantification also 
shows depletion in CKD but starting on day 7 (-42%, p<0.05) through to day 42 (-83%, 
p<0.001) (Figure 3.2.D). A non-specific CYP3A2 band was not quantified. 
3.4 Hepatic CYP3A2 & CYP2C11 Enzymatic Activity over 
CKD Progression 
Sequentially, CYP3A2 and CYP2C11 enzymatic activity was assessed from liver 
microsomes. CYP3A2 intrinsic activity in CKD rats decreased on day 3, recovered on day 
7 and fell again 3.6-fold by day 14, 13-fold by day 28 and nearly 14-fold lower than 
controls by day 42 (Figure 3.2.E). The intrinsic activity of CYP2C11 showed a 4.6-fold 
difference between CKD and control as early as day 7 and up to 12.8-fold difference by 
day 42 (Figure 3.2.F). Vmax, Km and intrinsic clearance are summarized (Table 3.2).  
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Figure 3.2. Relative mRNA expression, protein expression and enzymatic activity levels 
of CYP3A2 and CYP2C11. CYP3A2 (A) and CYP2C11 (B) mRNA expression and protein 
expression, CYP3A2 (C) and CYP2C11 (D), with representative western blots. Values 
were relative to β-actin represented as the mean ± SEM, normalized to control day 0 and 
arbitrarily defined as 100%. A non-specific band in CYP3A2 immunoblot was not 
quantified. Enzymatic activity of CYP3A2 (D) and CYP2C11 (E) in control and CKD rats 
represented as the mean intrinsic clearance Vmax/Km [(pmol/min/mg protein)/µM] of 
testosterone metabolite ± SEM. *p < 0.05 when compared to matching day control; n ≥ 6.  
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Table 3.2. CYP3A2 and CYP2C11 enzymatic activity over CKD progression. 6βOH-
testosterone (CYP3A2) and 16αOH-testosterone (CYP2C11) production of liver 
microsomes measured following incubation with NADPH and testosterone. *p<0.05 
compared to matching day control; n ≥ 6. 
 
6βOH-testosterone (CYP3A2) 
                 Vmaxa                    Kma Intrinsic Clearance (Vmax/Km)a 
Control CKD Control CKD Control CKD 
Day 0 35938±2841 35938±2841 29.5±9.02 29.5±9.02 1275±393.87 1275±393.87 
Day 3 56184±5640 26425±2097* 40.1±14.46 29.8±9.13 1422±540.42 894±288.25* 
Day 7 49912±1806 42396±4911 40.2±5.218 42.7±17.48 1272±214.04 1036±489.05 
Day 14 38223±2797 12804±1983* 49.4±12.34 59.4±29.88 804±207.09 222±152.72* 
Day 28 61702±3069 10102±1289* 66.6±10.43 141.6±44.74* 936±86.36 71±21.50* 
Day 42 45706±2266 7849±1297* 58.5±9.46 135.6±56.32* 795±139.12 58±24.76* 
 16αOH-testosterone (CYP2C11) 
                 Vmaxa                    Kma Intrinsic Clearance (Vmax/Km)a 
Control CKD Control CKD Control CKD 
Day 0 17983±1210 17983±1210 14.2±4.56 14.2±4.56 1365±518.05 1365±518.05 
Day 3 25892±2353 15453±1195 21.8±8.28 13.8±5.13 1202±298.73 1123±357.65 
Day 7 41420±2488 27114±3431 14.3±4.09 23.5±12.17 2907±541.70 1206±607.94* 
Day 14 51824±2556 17521±2406* 16.9±3.75 18.6±11.18 3199±377.15 948±523.91* 
Day 28 72358±2064 16236±1548* 20.1±2.45 21.2±8.52 3679±548.84 797±273.19* 
Day 42 62571±3147 6658±513* 16.2±3.71 22.6±7.21 4005±570.00 312±179.33* 
aVmax, Km and intrinsic clearance (Vmax/Km) were obtained by Michaelis-Menten kinetics.  
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3.5 Plasma & Liver Metabolomics 
Having demonstrated changes in mRNA, protein levels and enzymatic activity in the CYP 
enzymes, I next performed an untargeted metabolomics analysis by MS to assess changes 
in metabolite composition. Principle component analysis (PCA) clearly separated CKD 
and control for both rat plasma and liver samples (Figure 3.3). Early disease stages are 
arbitrarily defined as day 3-14 and late stages days 28 and 42. A loadings biplot for each 
run shows the position of each loading/metabolite (Figure 3.4). OPLS-DA plots were 
generated for each of the twenty comparisons across all four runs. OPLS-DA plots 
comparing control versus CKD at each time point for the plasma RPLC run provide an 
example for the other three runs (Figure 3.5). R2 and Q2 parameters were used to 
accompany the interpretation of OPLS-DA plots and R2/Q2 ratio < 2 represent results with 
high reproducibility between control and CKD on each day (Table 3.3). Metabolites in rat 
plasma were well separated from control as early as day 3 when using RPLC (Figure 
3.3.A). Liver RPLC showed far less separation between control and CKD before day 28 
(Figure 3.3.B). The HILIC column showed separation back to day 7 except for poor Q2 
values on day 14 in both plasma and liver samples (Figure 3.3.C-D). 
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Figure 3.3. Unsupervised principle component analysis (PCA) plots of rat plasma (A) and 
liver (B) metabolome separated by RPLC. PCA of plasma (C) and liver (D) metabolome 
separated by HILIC. Each point is either control (), early stage CKD defined by day 3, 7 
and 14 (), or late stage CKD defined by days 28 and 42 (). Each axis is either the first 
[1], second [2] or third [3] principle component showing the two components representing 
the largest variation between groups and displayed as a percentage of component 
contribution. Placement of each sample is determined by the metabolite composition within 
each sample and clustered samples share similar compositions. Data is centered and Pareto-
scaled. Select rat samples were removed as outliers (A) no outliers, (B) a day 3 and day 42 
control, (C) a day 28 CKD sample, and (D) a day 7 control sample. 
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Figure 3.4. Loadings biplot of rat plasma (A) and liver (B) metabolome separated by RPLC 
and plasma (C) and liver (D) metabolome separated by HILIC. Each point is either a sample 
control (), early stage CKD defined by day 3, 7 and 14 (), late stage CKD defined by 
days 28 and 42 (), or a metabolite loading (). Metabolites PS (i), EPS (ii) and IS (iii) 
are indicated. Each axis is either the first [1], second [2] or third [3] principle component 
showing the two components representing the largest variation between groups and 
displayed as a percentage of component contribution. Data is centered and Pareto-scaled. 
Select rat samples were removed as outliers (A) no outliers, (B) a day 3 and day 42 control, 
(C) a day 28 CKD sample, and (D) a day 7 control sample. 
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Figure 3.5. OPLS-DA plots generated from the PCA of rat plasma separated by RPLC for 
day 3 (A), day 7 (B), day 14 (C), day 28 (D) and day 42 (E). Each point is a control () or 
CKD () sample. Each axis is the first [1] and second [2] principle component representing 
the largest variation between supervised groups and displayed as a percentage of 
component contribution. 
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Table 3.3. Multivariate OPLS-DA parameters R2 and Q2. R2 and Q2 values for plasma and 
liver metabolomics using RPLC and HILIC across all time points.  
ǂ Values indicate poor predictability. *Abnormal values, considered poor predictability. Comp No. = 
principle component number. 
  Rat Plasma 
RPLC HILIC 
D
a
y 
4
2
 Comp No. R2 Q2 R2/Q2 Comp No. R2 Q2 R2/Q2 
[1] 0.9859 0.9175 1.0745 [1] 0.9821 0.5936 1.6546 
[2] 0.9859 0.9493 1.0385 [2] 0.9821 0.8064 1.2180     
[3] 0.9821 0.8677 1.1319 
D
a
y 
2
8
 
Comp No. R2 Q2 R2/Q2 Comp No. R2 Q2 R2/Q2 
[1] 0.9982 0.6410 1.5572 [1] 0.9734 0.8402 1.1586 
[2] 0.9982 0.8176 1.2210 [2] 0.9734 0.9491 1.0255         
D
a
y 
1
4
 
Comp No. R2 Q2 R2/Q2 Comp No. R2 Q2 R2/Q2 
[1] 0.8940 0.5438 1.6439 [1] 0.7248 0.2872ǂ 2.5240ǂ 
[2] 0.8940 0.5203 1.7181 [2] 0.7248 0.5121 1.4152         
D
a
y 
7
 Comp No. R2 Q2 R2/Q2 Comp No. R2 Q2 R2/Q2 
[1] 0.9628 0.5418 1.7770 [1] 0.9169 0.5979 1.5336 
[2] 0.9628 0.7150 1.3466 [2] 0.9169 0.8431 1.0876         
D
a
y 
3
 Comp No. R
2 Q2 R2/Q2 Comp No. R2 Q2 R2/Q2 
[1] 0.8680 0.5969 1.4542 [1] 0.9873 0.2812ǂ 3.5112ǂ 
[2] 0.8680 0.5420 1.6016 [2] 0.9873 0.6354 1.5538     
[3] 0.9873 0.7510 1.3146 
 Rat Liver 
RPLC HILIC 
D
a
y 
4
2
 Comp No. R2 Q2 R2/Q2 Comp No. R2 Q2 R2/Q2 
[1] 0.9753 0.7750 1.2585 [1] 0.9832 0.8722 1.1273 
[2] 0.9753 0.8708 1.1200 [2] 0.9832 0.9194 1.0694 
[3] 0.9753 0.9214 1.0585 
    
D
a
y 
2
8
 
Comp No. R2 Q2 R2/Q2 Comp No. R2 Q2 R2/Q2 
[1] 0.9691 0.7830 1.2377 [1] 0.9900 0.9034 1.0958 
[2] 0.9691 0.9284 1.0438 [2] 0.9900 0.9286 1.0661         
D
a
y 
1
4
 Comp No. R2 Q2 R2/Q2 Comp No. R2 Q2 R2/Q2 
[1] 0.8357 0.0070*ǂ 118.877*ǂ [1] 0.9712 0.4582ǂ 2.1194ǂ 
[2] 0.8357 0.2953ǂ 2.8298ǂ [2] 0.9712 0.6679 1.4541     
[3] 0.9712 0.7677 1.2651 
D
a
y 
7
 Comp No. R
2 Q2 R2/Q2 Comp No. R2 Q2 R2/Q2 
[1] 0.9973 0.3534ǂ 2.8218ǂ [1] 0.9512 0.5142 1.8498 
[2] 0.9973 0.7233 1.3787 [2] 0.9512 0.7394 1.2864 
[3] 0.9973 0.8425 1.1837 
    
D
a
y 
3
 Comp No. R
2 Q2 R2/Q2 Comp No. R2 Q2 R2/Q2 
[1] 0.8938 0.5384 1.6601 [1] 0.9512 0.5142 1.8498 
[2] 0.8938 0.5749 1.5548 [2] 0.9512 0.7394 1.2864     
[3] 0.9873 0.7510 1.3146 
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3.6 DME & Uremic Toxins 
After establishing changes in the metabolomic profile by PCA, metabolites were correlated 
to CYP mRNA, protein and enzymatic activity after satisfying multivariate and univariate 
analysis. 204 m/z ratios were identified across all four runs that correlated with either 
CYP3A2 or CYP2C11 (Supplementary Table 3. Appendix B). Of these 204 m/z ratios, 9 
metabolites were identified at identification level 1 using purchased standards. These 
metabolites include: Allantoin, L-carnitine, creatinine, 2,8-dihydroxyadenine, equol-4/7-
O-glucuronide, 4-ethylphenyl sulfate, IS, pantothenic acid (vitamin B5) and PS (Table 3.4). 
IS, PS and 4-ethylphenyl sulfate concentrations across both plasma and liver samples using 
RPLC were quantified via standard curve. All three metabolites show significantly 
increased concentrations (p<0.0001) on days 28 and 42 for both plasma and liver tissue 
(Figure 3.6). 
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Table 3.4. Metabolites classified level 1 from CKD and control rat plasma and liver 
untargeted metabolomics.  
aMass error was obtained using the 4th decimal place m/z from the Human Metabolome Database (HMDB). 
bP = Plasma; L = Liver. cMetabolites satisfying univariate analysis and Spearman correlation to same-sample 
CYP3A2 or CYP2C11 data with correlation coefficients (r value) listed. 2-way independent ANOVA was 
conducted via MetaboAnalyst v3.0 (Wishart et al., 2013) using FDR<0.05 to correct for multiple 
comparisons and satisfaction required p<0.05 across both “Time” and “Disease”. dMultivariate analysis 
required VIP > 0.8 and 0.4 < p(corr)[1] < -0.4 indicating adequate separation by OPLA-DA and S-plot.  
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1 2 181.0328 0.57 
C4H6N4O3 
(M+Na) 
Allantoin P RPLC (+) -0.7254 -0.7073 FALSE 
1 5 
157.0359 0.56 
C4H6N4O3 
(M-H) 
Allantoin 
L RPLC (-) -0.7284 -0.7920 FALSE 
157.0360 0.57 P RPLC (-) -0.7391 -0.7921 FALSE 
1 1 162.1123 0.53 
C7H15NO3 
(M+H) 
L-Carnitine P RPLC (+) 0.6694 0.8657 TRUE 
1 0 114.0662 3.24 
C4H7N3O 
(M+H) 
Creatinine P HILIC (+) -0.7029 -0.6590 TRUE 
1 1 168.0515 4.56 
C5H5N5O2 
(M+H) 
2,8-
Dihydroxyadenine 
P HILIC (+) -0.7336 -0.6860 FALSE 
1 2 417.1182 1.85 
C21H22O9 
(M-H) 
Equol 4/7-O-
Glucuronide 
L RPLC (-) -0.7265 -0.8050 TRUE 
1 3 
201.0221 1.06 
C8H10O4S 
(M-H) 
4-Ethylphenyl 
Sulfate 
L HILIC (-) -0.6689 n/a TRUE 
201.0221 2.13 L RPLC (-) -0.7387 n/a TRUE 
201.0221 2.10 P RPLC (-) -0.6813 n/a TRUE 
1 3 
212.0016 1.65 
C8H7NO4S 
(M-H) 
Indoxyl Sulfate 
L RPLC (-) -0.7201 n/a TRUE 
212.0017 1.65 P RPLC (-) -0.7072 n/a TRUE 
1 0 220.1179 2.23 
C9H17NO5 
(M+H) 
Pantothenic Acid P HILIC (+) n/a -0.7160 TRUE 
1 3 
172.9909 1.27 
C6H6O4S 
(M-H) 
Phenyl Sulfate 
L HILIC (-) -0.6914 -0.6770 TRUE 
172.9906 1.59 L RPLC (-) -0.726 -0.6840 TRUE 
172.9907 1.38 P HILIC (-) -0.6848 -0.6500 TRUE 
172.9906 1.57 P RPLC (-) -0.6902 n/a TRUE 
55 
 
 
Figure 3.6. Quantitative analysis of metabolites IS, PS and EPS. Plasma IS (A), PS (C), 
EPS (E) (µM) and liver IS (B), PS (D) and EPS (F) (pmol/mg liver tissue) concentrations 
obtained via untargeted metabolomics. Results are presented as mean ± SEM, *p < 0.0001 
when compared to same day control; n≥6.  
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3.7 Caecal Microbiota 
To understand if the gut microbiota was changing in parallel with metabolite changes, next-
generation Illumina sequencing was used to assess the bacterial composition of the caecum. 
Following data processing of Illumina sequencing reads, 1199 bacterial OTUs were 
identified (Supplementary Table 2. Appendix B). Unsupervised PCA analysis separated 
caecum samples primarily by time, regardless of disease state along the first principle 
component (Figure 3.7.A). The PCA also clearly separated CKD and control groups at day 
28 and 42 on the second principle component (day 28: R2 = 0.97; Q2 =0.71 and day 42: R2 
= 0.98; Q2 =0.70) (Figure 3.7.B). The ALDEx2 R package (Fernandes et al., 2014; Gloor 
et al., 2016a) was used to compare the relative bacterial abundances responsible for the 
observed clustering on each day. Using effect size and overlap statistical thresholds, 
relative abundance of each OTU was tabulated and assessed for trends (Table 3.5). Only 
two bacterial OTUs changed between control and CKD on two or more consecutive days 
with respect to effect size and overlap. The first OTU was from the phylum Firmicutes and 
genus Turicibacter and was significantly higher in CKD rats compared to control animals 
on days 14, 28 and 42 (Figure 3.8.A) with an increasing trend associated with disease 
progression. The second OTU from phylum Bacteroidetes and genus Parabacteroides 
showed a significant decrease in control rats over time, but CKD rats did not show a similar 
decrease on days 28 and 42 (Figure 3.8.B). 
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Figure 3.7. Unsupervised principle component analysis (PCA) of control and CKD rat 
caecum bacterial sequences coloured by (A) day 0 () 3 (), 14 (), 28 () and 42 () 
or by (B) treatment, CKD () or control (). Data is centered without scaling.  
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Table 3.5. Relative abundances of caecal bacteria. Taxonomy of bacteria with relative 
abundance effect sizes > 1.5 or < -1.5 and overlap of < 6.5% across days 3, 14, 28 and 42 
obtained using R v3.2.3 package ALDEx2 v1.2.0; n ≥ 6 per group.  
Phylum Class Order Family Genus 
Effect 
Sizea 
Overlap 
(%) 
OTU # | 
% Identity 
Day 3 
Firmicutes Clostridia Clostridiales Lachnospiraceae Blautia -1.97744 0.02% 52|73 
Day 14 
Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus 1.57949 1.82% 15|96 
Firmicutes Clostridia Clostridiales Clostridiaceae_1 Clostridium* -1.91316 2.86% 7|100 
Firmicutes Clostridia Clostridiales Lachnospiraceae Acetatifactor -1.28995 5.45% 105|77 
Firmicutes Clostridia Clostridiales Lachnospiraceae unclassified 1.59802 2.86% 1089|100 
Firmicutes Clostridia Clostridiales Lachnospiraceae unclassified 2.79302 0.02% 5|100 
Firmicutes Erysipelotrichia Erysipelotrichales Erysipelotrichaceae Allobaculum -1.59115 4.43% 17|100 
Firmicutes Erysipelotrichia Erysipelotrichales Erysipelotrichaceae Turicibacter -1.62785 2.08% 31|100 
Day 28 
Actinobacteria Actinobacteria Bifidobacteriales Bifidobacteriaceae Bifidobacterium 3.33811 0.02% 35|100 
Bacteroidetes Bacteroidia Bacteroidales S24-7 unclassified 1.35053 3.65% 37|100 
Bacteroidetes Bacteroidia Bacteroidales S24-7 unclassified 1.73352 1.56% 1131|100 
Bacteroidetes Bacteroidia Bacteroidales unclassified unclassified -1.42179 4.94% 0|86 
Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Parabacteroides -1.64147 6.23% 38|100 
Firmicutes Clostridia Clostridiales Lachnospiraceae unclassified 2.67131 0.02% 95|99 
Firmicutes Clostridia Clostridiales Ruminococcaceae unclassified 1.35584 6.25% 33|100 
Firmicutes Erysipelotrichia Erysipelotrichales Erysipelotrichaceae Allobaculum 1.54968 2.34% 71|100 
Firmicutes Erysipelotrichia Erysipelotrichales Erysipelotrichaceae Allobaculum 1.85920 0.26% 42|100 
Firmicutes Erysipelotrichia Erysipelotrichales Erysipelotrichaceae Allobaculum 1.89318 0.02% 81|100 
Firmicutes Erysipelotrichia Erysipelotrichales Erysipelotrichaceae Allobaculum 3.59784 0.02% 17|100 
Firmicutes Erysipelotrichia Erysipelotrichales Erysipelotrichaceae Turicibacter -1.87746 1.04% 31|100 
Day 42 
Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Parabacteroides -2.04878 0.02% 38|100 
Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Parabacteroides -1.77505 5.73% 32|100 
Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides -1.54895 5.45% 48|100 
Bacteroidetes Bacteroidia Bacteroidales S24-7 unclassified 1.40509 4.16% 134|100 
Bacteroidetes Bacteroidia Bacteroidales S24-7 unclassified 1.63886 3.38% 50|100 
Bacteroidetes Bacteroidia Bacteroidales S24-7 unclassified 1.85022 3.38% 8|100 
Firmicutes Bacilli Lactobacillales Lactobacillaceae Lactobacillus -2.02905 3.38% 30|100 
Firmicutes Clostridia Clostridiales Ruminococcaceae Ruminococcus -1.56150 4.69% 83|100 
Firmicutes Clostridia Clostridiales Ruminococcaceae Oscillibacter 1.31799 5.71% 20|100 
Firmicutes Clostridia Clostridiales Lachnospiraceae Blautia 1.31819 4.16% 139|98 
Firmicutes Erysipelotrichia Erysipelotrichales Erysipelotrichaceae Allobaculum 1.40698 4.94% 81|100 
Firmicutes Erysipelotrichia Erysipelotrichales Erysipelotrichaceae Turicibacter -2.17912 0.26% 31|100 
unclassified unclassified unclassified unclassified unclassified -1.86555 5.45% 54|100 
aPositive effect sizes indicate bacteria with higher relative abundance in control while negative values 
indicate bacteria with a higher relative abundance in CKD. Bolded values indicate bacteria with -2 > effect 
size > 2 and overlap < 0.03%. *Clostridium_sensu_stricto_1.  
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Figure 3.8. Average relative abundance of genus Turicibacter (A) and genus 
Parabacteroides (B) displayed as an average relative abundance ratio of all OTUs ± 95% 
confidence interval using R v3.2.3 package ALDEx2 v1.2.0. *Effect size < -1.5 and overlap 
< 6.5% compared to same day control; n ≥ 6.   
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Chapter 4  
4 Discussion 
The pharmacokinetics of many drugs are unpredictably altered in CKD and these patients 
are susceptible to ADEs (Corsonello et al., 2005; Manley et al., 2005). Hepatic DMEs such 
as CYP3A4 and CYP2C9 are responsible for the non-renal drug clearance of nearly half of 
all marketed pharmaceuticals. It is therefore suggested that DMEs play a role in the altered 
pharmacokinetics of CKD. Although studies on the downregulation of CYPs in CKD 
patients are ongoing, animal models clearly identify downregulation associated with loss 
of renal clearance and subsequent retention of uremic toxins where mechanistic studies 
currently suggest a wide array of pathways from pre-transcriptional regulation through to 
direct inhibition of DMEs by uremic toxins, inflammatory factors and hormones (Guévin 
et al., 2002; Sun et al., 2004; Michaud et al., 2006, 2008; Barnes et al., 2014; Velenosi et 
al., 2014; Volpe et al., 2014; Yeung et al., 2014). Uremic toxins are also suggested to 
change the environment of the gut, altering the relative abundance of gut bacteria favouring 
uremic-toxin producing microbes and creating a state of dysbiosis in CKD patients (Wong 
et al., 2014; Felizardo et al., 2016; Vaziri, 2016). Further, metabolites or toxins produced 
by the altered microbiota may fuel the cycle of CKD progression and potentially DME 
downregulation. However, the pathophysiological factors of uremia and dysbiosis had yet 
to be tested temporally. In this thesis, uremia and dysbiosis have been characterized over 
CKD progression to identify potential causes of DME downregulation. Metabolite and 
bacterial profiles were compared to the expression and activity of CYP3A2 and CYP2C11 
in an attempt to support my hypothesis that uremic toxins and/or bacterial alterations are 
temporally associated with changes in DME regulation. 
4.1 Conclusions 
4.1.1 CKD Characterization 
As expected, urea and creatinine levels increased non-linearly in response to adenine-
induced CKD (Kobayashi et al., 2014; Feere et al., 2015). Both disease markers urea and 
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creatinine confirmed CKD induction by day 14 which increased in severity through to the 
end of the study and matched with kidney histology (Figure 3.1). Pathohistological features 
including enlarged nephron tubules, areas of fluid retention, inflammation, atrophy and 
adenine deposits were seen in diseased kidneys after day 14 as observed in previous studies 
using this model (Ali et al., 2013). Body weights were unchanged between groups, due to 
the validity of the pair-feeding method (Figure 3.2). 
4.1.2 DMEs over CKD Progression 
CYP3A2 and CYP2C11 DMEs were both negatively impacted by CKD on all three levels 
of detection as previously observed (Hashimoto et al., 1997; Velenosi et al., 2012). The 
enzymatic activity and protein levels mirror what is seen in mRNA expression suggesting 
that DMEs are influenced at a transcriptional level, influencing the production of protein 
and ultimately enzyme activity. CYP3A2 has stable expression in control rats while in 
CKD, levels decrease starting on day 14. These observations suggest a constitutive factor 
required for expression is being removed, inhibited or downregulated. Although further 
studies are required, this could be mediated by the increase in uremic toxins discussed in 
section 4.1.4 (Wright et al., 1997). In contrast, CYP2C11 shows an increase in control rats 
as early as day 7 but a failure to increase in CKD rats. The increase in control CYP2C11 
has been noted previously in healthy male rat juveniles where it is suspected to reflect the 
increase of endogenous substrate testosterone during puberty (Wright et al., 1997; Yun et 
al., 2010). The testosterone levels in male Wistar rats are known to increase starting at 25 
days of age and peaking at 60 days of age (Ghanadian et al., 1975). The estimated age of 
our rats is 60 days of age on day 28 of the study which aligns with our observed peak in 
CYP2C11 mRNA on day 28 (Figure 3.2.B). This may suggest we are capturing the end of 
puberty and testosterone peak where CKD may be inhibiting the testosterone peak in these 
adolescent rats. Additionally, CKD is known to impact male patients by causing 
hypogonadism associated with decreased levels of testosterone further suggesting a 
hormonal role in CYP regulation  (Carrero et al., 2011). CYP2C11 is also influenced by 
alterations in the normally cyclic levels of growth hormone (GH) where continuous GH 
release or complete loss of GH production will both downregulate CYP2C11 (Kaufhold et 
al., 2002). Interestingly, one-third of pediatric CKD patients experience GH insensitivity 
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and stunted stature (Cayir & Kosan, 2015; Akchurin et al., 2017). It is therefore possible 
that the rat CYP2C11 downregulation is due to insufficient levels of substrate testosterone 
or irregular production of GH. However, testosterone was not identified as a correlated 
metabolite and GH was not targeted for analysis.  
Perhaps the differing trends seen between CYP3A2 and CYP2C11 are attributed to nuclear 
receptor differences. CYP2C11 is shown to be less dependent on HNF-4α induction, and 
CKD-induced receptor binding inhibition is less extensive for CYP2C11 than it is CYP3A2 
(Honkakoski & Negishi, 2000; Velenosi et al., 2014; Feere et al., 2015). Alternatively, it 
is possible that the inactivation of shared nuclear receptor PXR  or reduced receptor binding 
capacity of RNA polymerase II is more severe for CYP2C11; however, this has yet to be 
tested (Mikamo et al., 2003; Velenosi et al., 2014; Feere et al., 2015).  
Enzymatic activity effectively produced the same trend as mRNA and protein results for 
both enzymes. However, CYP3A2 Km showed a significant increase between CKD and 
control on days 28 and 42. The increased Km suggests the concentration of substrate 
testosterone required to obtain the same half-maximal velocity (Vmax/2) has increased. This 
could be explained by i) the upregulation of another enzyme with substrate specificity for 
testosterone, or more likely, ii) an alternate CYP3A2 substrate associated with CKD days 
28 and 42 was bound to CYP3A2 prior to microsome isolation and had a stronger binding 
affinity than testosterone (Berg et al., 2012). This occurred in another study using 4-
hydroxylation of triazolam (Toda et al., 2009) although the reason was unexplained. 
Overall, we can conclude that both CYPs studied herein are negatively regulated in CKD 
at the transcriptional and expression levels, and CYP2C11 changes occur earlier than those 
of CYP3A2. 
4.1.3 Metabolome over CKD Progression 
Untargeted metabolomics analyzed by PCA showed that plasma RPLC allowed for the 
greatest magnitude of separation between control and CKD rats when compared to plasma 
HILIC separation. By PCA visualization, plasma samples showed greater separation in 
earlier stages of disease (days 3-14) than the liver samples. Unlike the plasma samples, 
liver metabolites were better differentiated with the HILIC column. This suggests CKD 
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first inflicts a uremic environment in the plasma before infiltrating the liver, which is the 
physiological expectation since the reduced GFR in CKD directly increases uremic toxin 
concentration at the glomerulus before the blood is cycled through the liver. This also tells 
us that uremic changes overlap with the early changes in CYP3A2 and CYP2C11, 
supporting the hypothesis that uremic toxins are involved with DME regulation. 
4.1.4 Uremic Toxins Correlated with DMEs 
Metabolites from each run were subjected to correlation analysis with CYP3A2 or 
CYP2C11 mRNA, protein or enzymatic activity levels. Of the 204 m/z ratios retrieved, 8 
of the 9 identified at level 1 classification were seen to increase with CKD progression 
[allantoin, creatinine, 2,8-dihydroxyadenine, pantothenic acid (vitamin B5), IS, PS, equol-
4/7-O-glucuronide and 4-ethylphenyl sulfate]. L-carnitine was the only level 1 metabolite 
that showed a positive correlation with CYP downregulation and thus decreased over CKD 
progression. 
Allantoin and creatinine are non-protein bound metabolites successfully eliminated by 
dialysis (Meyer & Hostetter, 2007). This makes them potentially less harmful than their 
protein-bound counterparts, and in general, the implications of non-protein bound uremic 
toxins with relation to drug metabolism or altered pharmacokinetics has largely been 
overlooked. Allantoin is an expected component of uremia because it is the primary 
elimination product of uric acid and increases are observed in the plasma and urine of CKD 
rats induced by 5/6th nephrectomy or adenine (Akiyama et al., 2012; Zhao et al., 2013a, 
2013b). Here we also find allantoin in rat liver, suggesting further infiltration due to 
advanced uremia. Allantoin is generally not produced by humans because we lack uricase 
activity although allantoin has been detected in CKD patients (Toyohara et al., 2010; Niwa, 
2013). Allantoin in humans is suggested to reflect the presence of uric acid-converting 
reactive oxygen species; however, it could provide evidence for uric acid translocation into 
the gut. Bacteria in our gut possess uricase activity and are capable of producing allantoin, 
although studies are needed to confirm this hypothesis (Zhao et al., 2013a; Wong et al., 
2014). 
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As discussed (see section 1.3.3), creatinine is a product of creatine and the most common 
marker of glomerular function used as a clinical tool to calculate eGFR. CYP3A2 and 
CYP2C11 both correlate with creatinine and urea, the two disease markers defining CKD 
in this model. Since creatinine increases with respect to CKD and DMEs correlate with 
CKD onset, creatinine by default will correlate with DME downregulation. However, 
creatinine involvement with DME regulation has been overlooked and little is known about 
its pathophysiological impact in CKD. Studies have established that of all creatinine in a 
patient experiencing renal failure, a variable 16-66% undergoes metabolic clearance (Wyss 
& Kaddurah-Daouk, 2000). Interestingly, up to 68% of creatinine cleared by metabolism 
is hypothesized to be converted back to creatine by creatininase-possessing bacteria of the 
gut, suggesting creatinine translocation across the gut lumen (Wyss & Kaddurah-Daouk, 
2000). The creatine can then i) return to the plasma via enteric cycling explaining raised 
levels of creatine in CKD patients, ii) or continue to be metabolized by gut bacteria to end-
products 3,1-methylhydantoin or glycolate (Wyss & Kaddurah-Daouk, 2000). 
Alternatively, creatinine can undergo oxidation to methylguanidine or methylurea of which 
methylguanidine has been identified as a harmful uremic toxin, progressing CKD when 
administered to rats (Wyss & Kaddurah-Daouk, 2000). Ultimately, more information on 
the toxic or adverse effects of creatinine and its degradation products need to be established 
with respect to DME regulation in CKD (Storm et al., 2013).  
2,8-Dihydroxyadenine, the adenine metabolite responsible for the induction of CKD, is 
also associated with CYP3A2 and CYP2C11. 2,8-Dihydroxyadenine induces CKD in a 
mechanistic, concentration-dependent manor and thus, DMEs correlating with CKD onset 
are expected to correlate with 2,8-dihydroxyadenine (Terai et al., 2008). Since DMEs are 
downregulated in other models of CKD, it is unlikely that 2,8-dihydroxyadenine is 
impacting DME regulation directly (Leblond et al., 2002; Velenosi et al., 2014; Feere et 
al., 2015). 
Pantothenic acid (vitamin B5) is an essential nutrient found in many foods, including the 
provided rat chow, that is metabolized into coenzyme A, a molecule necessary for healthy 
biochemical synthesis and energy metabolism (Berg et al., 2012). However, pantothenic 
acid has rarely been associated with toxic effects nor has any tolerable upper dosage been 
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established (Institute of Medicine, 1998; Kelly, 2011). An elegant study of organic anion 
transporter 1 (Oat1) suggests pantothenic acid requires Oat1 transport since it is 
accumulated in the plasma of Oat1 knockout mice (Wikoff et al., 2011). Additionally, 
administration of probenecid, a drug known to inhibit Oat transporters, increases plasma 
pantothenic acid levels (Kelley, 1975; Niwa, 2013). The proposed inhibition of OATs in 
CKD is associated with high-affinity uremic substrates, effectively incapacitating OAT 
function and likely causing the increase of pantothenic acid by inhibiting its movement 
though excretory pathways (Nigam et al., 2015). Pantothenic acid has not been studied as 
a modulator of DMEs possibly because it is considered non-toxic. However, studies are 
required to confirm the presence of seemingly non-toxic endogenous metabolites like 
pantothenic acid are not modulating DMEs. 
Gut derived uremic toxins that have prospect for being involved in DME downregulation 
from this study include IS, PS, 4-ethylphenyl sulfate, equol-4/7-O-glucournide and 
products of L-carnitine metabolism. IS and PS are two highly retained gut-derived uremic 
toxins (Wikoff et al., 2011; Leong & Sirich, 2016) both found in CKD patients and animal 
models (Itoh et al., 2012; Zhao et al., 2013a; Velenosi et al., 2016). IS and PS are linked 
to CKD comorbidities such as CVD (Hung et al., 2017) and have been associated with 
uremic influences of drug metabolism both through transcriptional regulation (Guévin et 
al., 2002), and IS as a direct inhibitor of CYP activity (Volpe et al., 2014). Thus, IS and 
PS found in this study support previously described roles in modifying CYP regulation in 
CKD. 
Equol-4/7-O-glucouronide (EOG) and 4-ethylphenyl sulfate (EPS) are both soy-derived 
uremic toxins seen in animal models fed a soy-based chow (Kikuchi et al., 2010; Velenosi 
et al., 2016). The rat chow in this experiment used 22% crude protein content of which 
daidzein and genistein aglycone equivalents (ranging from 350 to 650 mg/kg) were present. 
These isoflavones undergo bacterial transformation into equol derivatives such as EOG 
and EPS in the gut. EOG has only been found in animal models of CKD (Velenosi et al., 
2016) where EPS has been detected in dialysis patients, although without significant 
changes compared to healthy individuals (Itoh et al., 2012). Interestingly, EPS has a similar 
structure to p-cresyl sulfate, a metabolite usually found concomitant with IS and repeatedly 
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found in CKD (Itoh et al., 2013; Zhang & Davies, 2016). Due to the similar structure, the 
function of EPS is suspected to act similarly to p-cresyl sulfate which has been associated 
with deleterious human liver microsomal CYP3A4 regulation by direct inhibition (Barnes 
et al., 2014; Zhang & Davies, 2016; Gryp et al., 2017). It has yet to be assessed whether 
EPS can also directly inhibit the regulation of CYP3A2 or CYP2C11 in rats. 
L-Carnitine is a required nutrient primarily obtained through the diet in meat, eggs and 
protein-rich foods including soy (Klaassen & Cui, 2015). In contrast to an increase in L-
carnitine observed in the heart and kidney of adenine-induced CKD rats (Velenosi et al., 
2016), here we see a decrease in L-carnitine in the plasma in conjunction with 
downregulated CYPs in the liver. This could suggest a removal of L-carnitine as it is 
transformed into TMAO as seen previously (Koeth et al., 2013). L-Carnitine and choline 
are the precursors to TMA, a bacteria by-product that is converted to TMAO in the liver 
by flavin-containing monooxygenases (FMO) (Koeth et al., 2013). TMAO is associated 
with increased risk of developing atherosclerosis and thus, of increasing interest as a 
harmful uremic toxin in CKD and CVD (Koeth et al., 2013; Aron-Wisnewsky & Clément, 
2015). TMAO detection needs a sensitive MS method sometimes referred to as target 
enhancement, usually utilizing a triple quadropole MS rather than a QTof which is better 
for sensitivity (Heaney et al., 2016). Therefore, TMAO was missed by our untargeted 
methods because the sensitivity was insufficient (Heaney et al., 2016). Neither L-carnitine 
nor TMAO have been tested as DME regulatory factors but have been mentioned in 
relation to drug metabolism and provide potential candidates for future studies (Selwyn et 
al., 2015). 
The identification and correlation of these uremic toxins support their involvement in DME 
regulation. However, as discussed in section 1.7.1, administration of AST-120 in CKD, 
reduces uremic toxin levels (Kikuchi et al., 2010), but CYP3A2 expression is not recovered 
(Velenosi, 2015). This protection by AST-120 suggests factors other than uremic toxins 
may be involved. The quantified IS, PS and EPS concentrations over CKD progression 
observed in this thesis adds support to this idea (Figure 3.6). Severe concentrations (over 
150µM for IS) are not observed until following day 28, well after we observe a decrease 
in CYPs. Preliminary studies using Huh7 human hepatoma cells show that protein-bound 
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IS at concentrations of 180±20µM were required to reduce CYP3A4 expression by 50% 
(Velenosi, 2015). In addition, a similar study found that concentrations of IS required to 
downregulate CYP3A4 activity were above the abnormal range seen in CKD patients, 
which was defined as the highest ever recorded IS level in a CKD patient at >940µM 
(Vanholder et al., 2003; Volpe et al., 2014). Although the studies differ dramatically, 
collectively they suggest that other hypotheses such as immunological factors, PTH or 
undiscovered pathways might be initiating DME downregulation, and it is not until severe 
stages of CKD that uremic toxins contribute to the dramatic reduction in CYP expression 
seen here and by others (Velenosi et al., 2012). In conclusion, it is temporally plausible 
that uremic toxins contribute to DME downregulation, but other factors may be involved 
prior to uremic toxin influences.  
Interestingly, of the metabolites found by correlation to CYP3A2 or CYP2C11, the five 
metabolites that are potentially associated to DME downregulation in the literature are all 
gut-derived uremic toxins. This supports the need to understand the changes in the gut 
microbial environment and assess if bacterial alterations are impacting the presence of 
these toxins. 
4.1.5 Microbiome over CKD Progression 
The gut microbiota, sampled by caecum swab, was phylogenetically analyzed using 16S 
sequencing. Multivariate analysis showed the microbiota was most significantly influenced 
by time and secondarily by disease state. This correlation suggests that the microbiota 
changes caused by CKD induction are less profound than age-associated bacterial changes. 
Additionally, in comparison to the metabolomic PCA, microbial clustering with respect to 
disease state was poor and showed little to no separation before day 14. This observation 
suggests the uremic environment in the plasma and the liver are altered well before 
dysbiosis occurs. Interestingly however, the metabolite concentrations of IS, PS and EPS 
all dramatically increase after day 28 when changes are simultaneously observed in the gut 
microbiota. This lends support to the idea that uremia may be driving the change in gut 
microbial abundance through a damaged gut wall (Figure 4.1) (Magnusson et al., 1991; 
Felizardo et al., 2016; Vaziri, 2016). The late and dramatic increase in gut-derived uremic 
toxins also suggests dysbiosis contributes in the cycle of worsening uremia, likely adding 
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to the uremic milieu by increasing bacteria capable of uremic toxin production (Wong et 
al., 2014; Vanholder & Glorieux, 2015; Felizardo et al., 2016). Referencing the KEGG 
results of Wong and colleagues, all bacterial families significantly changed on days 28 and 
42 contained strains capable of producing at least one of the following genes: urease, 
tryptophanase, phosphotransbutyrylase or butyrate kinase, although the bacteria are 
inconsistently characteristic of control or CKD rats (Wong et al., 2014). The sole bacterial 
genus significantly changed due to disease state prior to day 14 resided in the bacterial 
order Clostridiales, which matched the findings of Barrios and colleagues who sequenced 
the gut microbiota of 855 people and correlated only bacteria from the Clostridiales order 
with eGFR in early renal decline (Barrios et al., 2015).  
Although interesting to examine the individual days for OTUs differing due to CKD, only 
two bacterial genera, Turicibacter and Parabacteroides, were significant on two or more 
consecutive days, best correlating with DME trends. Turicibacter was the most consistently 
changed bacteria, changing as early as day 14 through to day 42 with an increasing trend 
as CKD progressed. Identifying the genus Turicibacter in CKD animals is a novel finding. 
All Turicibacter are gram-positive, strictly anaerobic, rod-shaped bacteria of which very 
little is known. Turicibacter was first identified and named in 2002 by the University of 
Zürich, Switzerland where the bacteria were found in the blood of a febrile 35-year-old 
male with acute appendicitis (Bosshard et al., 2002). Shortly thereafter, another febrile 
patient diagnosed with acute appendicitis had Turicibacter cultured from their blood; this 
time a 79-year-old female in Sweden (Bosshard et al., 2002). In 2007, Turicibacter was 
associated with pouchitis in ulcerative colitis patients which is a complication of 
proctocolectomy (Falk et al., 2007). We also know Turicibacter sp. are found in healthy 
human feces from a FMT study where human feces were transplanted into colons of germ-
free rats to ascertain whether rats should be used as a transplantation model (Licht et al., 
2007). Turicibacter was one such bacteria that survived two weeks after transplantation via 
stool gavage.  
Only 4 strains, all within the same species sanguinis, have been published to date: MOL361 
(Bosshard et al., 2002), PC909 (Cuív et al., 2011), ZCY83 (Cao et al., 2015), H121 
(Auchtung et al., 2016). A BLASTn search of our Turicibacter sequence matched the 
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MOL361 species with 100% identity (NR_028816.1). Turicibacter is anaerobic and 
therefore, considerably difficult to culture. Of the strains successfully cultured, none have 
tryptophanase activity suggesting these bacteria are not involved in producing indole 
derivatives such as IS (Bosshard et al., 2002). The Erysipelotrichaceae family of which 
Turicibacter belongs does contain strains capable of butyrate and phosphotransbutyrylase 
activity, although this has yet to be confirmed in the Turicibacter genus (Wong et al., 2014). 
Assuming all rats were exposed to Turicibacter for the study duration, we suggest our 
findings indicate CKD animals are more susceptible to gut colonization by Turicibacter. 
The BLASTn results for the Parabacteroides genus OTU suggested 99% sequence identity 
to two stains of the species distasonis: strain ATCC 8503 (NR_074376.1) and JCM 5825 
(NR_041342.1). In 2006, Bacteroides distasonis was reclassified as Parabacteroides 
distasonis and thus, all subsequent information pertains to either classification (Sakamoto 
& Benno, 2006). Parabacteroides is a gram-negative, anaerobic, non-spore-forming genus. 
P. distasonis is present in the human gut and has been identified via PCR in fecal samples 
long before the existence of next-generation sequencing methods (Franks et al., 1998). P. 
distasonis is classified in the KEGG pathway database as an opportunistic pathogen 
capable of anaerobic infection (Xu et al., 2007). In a study of gut microbiota in Crohn’s 
disease, P. distasonis was more abundant in the control group, contradictory to expected 
findings (Mondot et al., 2011). More recently, components of P. distasonis have shown 
improvement of irritable bowel disease (IBD) in mice and have been suggested as a 
potential therapeutic for reduction of inflammation in IBD (Kverka et al., 2011). However, 
analysis of bacteria capable of generating phenol and indole compounds found P. 
distasonis proficient at producing p-cresol (Gryp et al., 2017) and IS (Zhang & Davies, 
2016). In general, it seems P. distasonis is potentially both harmful or beneficial depending 
on translocation, relative abundance and physiological state of the host. Our results show 
a unique trend where CKD rats have a stable level of Parabacteroides and controls slowly 
reduce the abundance of this genus after 28 days. Given the multitude of associations with 
disease, Parabacteroides may be taking advantage of the dysbiotic state in CKD when it is 
normally removed in controls by other healthy bacteria as a part of the progression in age-
associated microbial changes. 
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This data shows that DME regulation in CKD is initially mediated by changes independent 
of an altered gut microbiota; however, late and dramatic increases in both uremic toxins 
and the bacterial environment suggest the gut microbiota may influence DMEs in severe 
CKD. It also remains possible that in this late stage CKD, gut microbes are influencing 
DMEs through uremic-independent methods such as inflammatory factor production as 
suggested by germ-free studies that also see downregulation of CYPs (Toda et al., 2009; 
Claus et al., 2011; Selwyn et al., 2015). 
4.1.6 Summary 
In conclusion, global plasma and liver alterations of the metabolome over disease 
progression provide support for uremic toxins playing a role in DME downregulation. 
Alternatively, the early detection of DME downregulation and late surge of gut-derived 
uremic toxin concentrations suggest other factors are involved in DME regulation in early 
stages of CKD (Figure 4.1). A temporal association was established between severe CKD, 
caecal dysbiosis and increase in gut-derived uremic toxins IS, PS and EPS. This association 
supports the positive-feedback loop of uremia and dysbiosis suspected to drive severe CKD 
(Figure 4.1). 
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Figure 4.1. Temporal associations of uremia and dysbiosis with CYP3A2 and CYP2C11 
expression over CKD progression. Days (3 through 42) refer to rat study time points carried 
out in this thesis. CKD was characterized by urea and creatinine beginning on day 14 and 
correlating with the decrease in CYP3A2 expression. CYP2C11 expression decreased as 
early as day 7. Although plasma uremia may be involved as early as day 7 indicated by 
untargeted multivariate analysis, quantified uremic toxins were significantly increased only 
on days 28 and 42. Similarly, gut bacterial dysbiosis was detectable on days 28 and 42 
supporting the hypothesis of a positive-feedback cycle involving uremia and the gut 
microbiota. This study suggests there are likely other factors influencing DMEs in early 
stages of CKD. Images were modified from Servier Medical Art 
(http://www.servier.co.uk/medical-art-gallery). 
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4.2 Limitations 
The greatest limitation of this study is that causative conclusions cannot be made from vast 
cross-sectional data such as those obtained from sequencing or metabolomics. Results from 
these discovery-based methods instead provide whole-system comprehension of complex 
mechanistic processes and allows for discovery of previously unknown biological factors 
that drive future experiments assessing causation. 
4.2.1 Animal Model & Study Design 
Utilizing in vivo animal models is accompanied with limitations when used to understand 
human physiology. Human CYP expression is comparable to rat and mouse CYP 
expression through orthologous enzymes that largely perform the same tasks, yet some 
substrates are species-specific indicating the enzyme activities are not identical to their 
human orthologs (Nelson et al., 2004; Pan et al., 2016). Secondly, the induction of CKD 
is achievable through different methods. Adenine-induced CKD is a less invasive orally 
administered model in comparison to the more common 5/6th nephrectomy model and 
although not linear, it is suggested to provide a more consistent rate of CKD onset than 
5/6th nephrectomy (Terai et al., 2008). Applying a steady rate of CKD onset was important 
for our temporal study design. Conceptually however, the adenine model has been 
questioned as a CKD model because it could also represent an acute kidney injury (AKI) 
model. Adenine metabolites precipitate when concentrated, mechanically damaging the 
kidney tubules comparable to kidney stones (Engle et al., 1996; Morishita et al., 2011; 
Succar et al., 2017). Though separately defined in nephrology for clinical diagnosis, AKI 
is a risk factor for CKD and CKD is a risk factor for AKI, and thus, the adenine model 
continues to be used for either condition (Chawla et al., 2014). The adenine model also 
reduces the amount of food ingested during the first days of adenine-induction, requiring 
that pair-feeding be established. This is especially important for CYP expression analysis 
since CYPs are influenced by short-term fasting (Lammers et al., 2015). Lastly, it is 
unknown how adenine and its metabolites will affect the gut microbial environment apart 
from CKD. When ingested, adenine absorption is proposed to occur within the small 
intestine, earlier in the intestinal tract than the caecal sampling site (Salati et al., 1984). It 
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is noteworthy that the adenine metabolite 2,8-dihydroxyadenine was only detected in the 
plasma and not in the liver of CKD rats suggesting 2,8-dihydroxyadenine is unlikely to be 
impacting the liver. 
4.2.2 Time Point Inclusion 
Initial results from this study evaluated only rats sacrificed on day 0, 3, 14, 28 and 42 and 
suggested CYP expression and uremic toxin levels were changing between days 3 and 14. 
In the attempt to obtain as much information about the transition between early and late 
CKD, a second study included rats subjected to identical conditions for 7 days. Upon 
completion of the second study, preliminary CYP3A2 mRNA expression results showed 
day 0 control rats had decreased expression in comparison with the other control groups 
and essentially increased after 3 days (Figure 4.2). It was later identified that DME 
expression is impacted by short-term fasting (Lammers et al., 2015). Thus, a third study 
compared only control ad libitum fed animals with animals receiving the CKD pair-fed 
amount of control food. After 72 hours, it was found that DME levels of animals receiving 
reduced feed were equivalent to levels observed in day 3 control rats. Therefore, day 0 rats 
from the final study were carried onward as the control day 0 group for the remainder of 
the investigation (Figure 4.2).  
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Figure 4.2. Short-term fasting effects on CYP3A2 mRNA expression. A) Preliminary 
CYP3A2 mRNA expression data comparing rats fed ad libitum to rats pair-fed lower food 
volumes matching those consumed by CKD rats. Values are expressed as the mean ± SEM 
relative to housekeeping gene β-actin and normalized to the ad libitum group. *p<0.05 
using a one-way ANOVA with Holm-Sidak’s multiple comparisons test. B) CYP3A2 
mRNA expression results before and after accounting for short-term fasting effects by 
waiting to sacrifice 72 hours after pair-feeding is initiated. 
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However, this time sensitivity impacted bacterial sampling. All animals from which 
bacteria are sampled, ideally must eat and live in the same area and be exposed to all 
experiences that may introduce foreign bacteria to the same extent if the sample size is 
small and bacterial differences are expected to be detectable. Ideally, particularly in animal 
studies, this means the animals should all be bought at the same time in one shipment if 
being compared together. Since the animals from day 7 and day 0 were obtained from the 
supplier at different times than the original study, the gut microbiota variability was too 
large to assess as a whole and therefore removed from bacterial analysis, reducing the 
number of time points available for evaluation. 
4.2.3 “Omics” Method Limitations 
Although broadly encompassing, both the Illumina sequencing and untargeted 
metabolomics methods are limited. Even though the 16S rRNA gene is currently the gene 
of preference, it is highly conserved, limiting its resolution and accuracy to the genus level 
(Poretsky et al., 2014). Also, the development of short, overlapping pair-end reads enabled 
the use of 16S gene sequencing on the MiSeq platform given only a small section of the 
16S gene required sequencing (Poretsky et al., 2014). However, this requires that out of 
the nine variable regions (V1-V9), only a select few can be covered by the read length 
capabilities of the MiSeq (Caporaso et al., 2012). It has been identified that using different 
variable regions (V1 through V6) results in different subsets of identifiable bacteria 
(Chakravorty et al., 2007; Youssef et al., 2009). Therefore, the V4 variable region was 
chosen based on the most bacteria that could be detected and likely present within a caecal 
sample (Caporaso et al., 2011).  
Similarly, untargeted metabolomics can identify a vast number of metabolites in a single 
sample, but each metabolite is only detectable if the combination of sample preparation, 
UPLC column, chromatography and MS configuration are satisfactory for that metabolite. 
As an example, TMAO is likely present in our rat plasma samples, but is not detected 
because the MS method needs to be adjusted for sensitivity (Heaney et al., 2016). To obtain 
as many metabolite masses as possible, two columns of differing hydrophobicity and both 
positive and negative ionization modes were used. 
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4.2.4 Statistics 
In addition to method limitations, analysis methods were also limiting. Little continuity in 
genera abundance across time points was primarily caused by small sample size of <7 per 
group. The inter-individual variability, in addition to machine and sampling variability, 
effectively masked small changes caused by condition and required broad shifts in bacterial 
abundance to prove significance (Poretsky et al., 2014; Gloor et al., 2016a). Without 
increasing sample size, this could be somewhat circumvented by using a sequencing 
method with less error and greater read depth (e.g. Illumina HiSeq), potentially providing 
more bacterial associations (Caporaso et al., 2012). 
Correlative analysis between metabolites and DME levels was the second-best option after 
a univariate model capable of acquiring an independent, FDR corrected, 2-way ANOVA 
with multiple comparisons for each time point between CKD and same day control. 
Although an independent, FDR corrected 2-way ANOVA is obtainable via MetaboAnalyst 
v3.0, p-values do not indicate on which days the significance is occurring. To answer the 
question of when the metabolite is changing over time, multiple comparison analysis using 
Sidaks multiple comparisons test is generally applied to the 2-way ANOVA. However, 
MetaboAnalyst v3.0 is incapable of multiple comparison testing and alternative software 
including GraphPad are unable to hold the vast amount of information present in a 
metabolomics dataset. It is also possible that a custom R script be written to obtain this 
same goal. However, for this study, there were limited options for identifying at what day 
each metabolite was changing and related to CYP3A2 (day 14) and CYP2C11 (day 7) 
expression. Alternatively, Spearman correlation analysis was used to identify metabolites 
that exhibit a similar trend to DME changes over CKD progression. Unfortunately, this 
correlation analysis assumes that metabolite concentrations influencing DMEs are directly 
proportional to DME levels, potentially limiting the results. 
4.3 Future Studies 
This thesis has emphasized the need for research around DMEs in early stages of CKD. 
Specifically, it needs to be elucidated if DMEs are truly changed in humans with CKD, 
apart from animal models. Alternatives to the erythromycin breath test are essential to 
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understanding human CYP3A4 regulation. In the meantime, DME studies can improve the 
rodent-to-human physiological gap by employing humanized mouse models of CYP3A4 
or CYP2C9 along with other DMEs or transporters (Becker & Hewitson, 2013; Ladda & 
Goralski, 2016).  
Although it is established that dialysis can effectively change the bioavailability of drugs 
in humans, it has yet to be determined if dialysis changes DME levels (Atkinson & Umans, 
2009). In theory, if only protein-bound uremic toxins are affecting drug pharmacokinetics, 
dialysis will not improve DME levels. An in vitro study looked at CYP expression and 
activity following the implement of pre-dialysis versus post-dialysis serum in rat 
hepatocytes and showed a decrease in DMEs after only pre-dialysis serum suggesting 
uremic toxins involved in DME downregulation can be removed via dialysis (Michaud et 
al., 2008). Additional information on what metabolites are being removed, perhaps through 
MS methods, would help researchers identify metabolites worth targeting for causation 
analysis. In vivo models of dialysis have been established and would provide an interesting 
avenue for studying DME levels before and after dialysis (Mortier et al., 2002; Zareie et 
al., 2005).  
It would also prove helpful if the list of mechanistic causes of DME downregulation were 
assessed together to understand the extent to which each mechanism is contributing to the 
entire downregulation of DMEs. For example, one could introduce suspected uremic toxins 
such as IS, PS, EPS, EOG and TMAO to human cells in vitro or human liver microsomes 
ex vivo and subsequently test for direct inhibition of human CYP3A4 or CYP2C9 
expression alongside nuclear receptor binding alterations and detection of PTH and 
inflammatory factors.  
Studies are needed to assess the implications of specific bacteria on disease states. It is 
unclear if Turicibacter is normally found in the gut at very low abundance or a foreign 
bacterium infiltrating a weak host. It is also unknown if this bacterium is pathological or 
commensal in nature. It would be beneficial to confirm that CKD is not inducible via 
bacterial alterations such as infection with Turicibacter. This assessment could be 
accomplished by FMT to introduce CKD microbiota, potentially from human CKD 
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patients to germ-free mice to see if i) the mouse acquires CKD regardless of initial kidney 
damage, and ii) if the presence of CKD-associated bacteria can cause DME downregulation 
in the absence of uremia. In conjunction, caecal or fecal metabolomics would provide 
information about what metabolites reach the gut lumen and aid in dysbiosis.  
4.4 Relevance & Conclusions 
In general, future CKD therapies should be targeted not only to improve disease 
comorbidities and prolong the progression into ESRD, but also improve drug disposition 
to ensure the pharmaceuticals received are providing the highest efficacy attainable while 
avoiding drug toxicity. Emerging therapies still directed towards improving 
pathophysiology and uremia include uremic toxin removal (e.g. AST-120) and pro- or 
prebiotics to stimulate the reversal of dysbiosis (Ranganathan et al., 2006; Koppe et al., 
2015; Rossi et al., 2016; Yamamoto et al., 2016). Currently there is no prospect for FMT 
to benefit CKD patients, although it has proved largely successful for C. difficile infections 
and theoretically translatable to CKD (Persky & Brandt, 2000; Al Khodor & Shatat, 2016). 
Our results suggest that future therapeutic research for DME regulation be targeted in the 
areas of uremic toxin removal as a priority over the reestablishment of the gut microbiota 
because our results suggest uremic toxins provide a more likely candidate for early stage 
DME alteration. 
Ultimately, understanding the effects of uremia and bacteria with respect to CKD can help 
assess whether uremic toxins or the gut microbiota are potential therapeutic targets in DME 
regulation. Whether it be adsorption of uremic toxins or combating bacterial dysbiosis, 
providing emphasis for one method may drive future research in the direction of greatest 
efficacy. On a larger scale, knowledge of how DMEs fluctuate with respect to metabolites 
and bacteria could lead to improved clinical testing, dosing and prevention of adverse 
reactions. 
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Appendix B: Supplementary Information 
 
Supplementary Table 1. Table of barcoded primers used for Illumina sequencing. Refer 
to excel file (.xlsx) titled “Barcoded Primers for Illumina Sequencing”. 
Supplementary Table 2. Table of 1199 operational taxonomic units identified from 
Illumina sequencing. Refer to excel file (.xlsx) titled “Final OTU Table from Illumina 
Sequencing”. 
Supplementary Table 3. Table of 204 m/z ratios found by untargeted mass spectrometry 
from CKD and control rat plasma and liver samples and RPLC or HILIC chromatography. 
Refer to excel file (.xlsx) titled “Final Metabolite Table from UPLC-MS”. Metabolites 
satisfying univariate analysis and Spearman correlation to same-sample CYP3A2 or 
CYP2C11 mRNA, protein or enzyme activity data. Spearman correlation coefficients (r 
value) are listed. 2-way independent ANOVA was conducted via MetaboAnalyst v3.0 
using FDR<0.05 to correct for multiple comparisons and satisfaction required p<0.05 
across both Time and Disease. Multivariate analysis required VIP > 0.8 and 0.4 < p(corr)[1] 
< -0.4 indicating adequate separation by OPLA-DA and S-plot. Mass error was obtained 
using the 4th decimal place m/z from the Human Metabolome Database (HMDB). 
Italicized suspected metabolites refer to a group of plausible metabolites of similar 
structure. For definitions of identification levels refer to section 2.6.4.  
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